# PeptideScanner evidence objects: Cetrorelix

Every published version of the records placed with Cetrorelix, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json. Selected public evidence only; not medical advice.

- Objects: 56
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00244452-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT00244452

> PeptideScanner retained ClinicalTrials.gov record NCT00244452 at 2026-11-15T22:02:39.332Z. Its registry update date was 2008-03-31, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct00244452-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2008-03-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00244452-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct00244452-cetrorelix-v1
- Content SHA-256: `c1ab1bd8f1e3b5968d85c8949a79ea2ca3c3a8de884133be4cb909f8c982faab`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00244452 ([`ctg-observation-nct00244452-2008-03-31-5e057a18b8d3`](#source-ctg-observation-nct00244452-2008-03-31-5e057a18b8d3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00244452 at 2026-11-15T22:02:39.332Z. Its registry update date was 2008-03-31, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct00244452-2008-03-31-5e057a18b8d3`](#source-ctg-observation-nct00244452-2008-03-31-5e057a18b8d3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00244452 at 2026-11-15T22:02:39.332Z. Its registry update date was 2008-03-31, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct00244452-2008-03-31-5e057a18b8d3`](#source-ctg-observation-nct00244452-2008-03-31-5e057a18b8d3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00244452-2008-03-31-5e057a18b8d3`](#source-ctg-observation-nct00244452-2008-03-31-5e057a18b8d3))

### Sources

<a id="source-ctg-observation-nct00244452-2008-03-31-5e057a18b8d3"></a>
- **ClinicalTrials.gov record NCT00244452 · retained source version 2008-03-31:5e057a18b8d37bf91bab0c9cad56ca124d66e10f9348943bcdc9d3b07bb591ce** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00244452) (`ctg-observation-nct00244452-2008-03-31-5e057a18b8d3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00244452." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct00244452-cetrorelix-v1 SHA-256: c1ab1bd8f1e3b5968d85c8949a79ea2ca3c3a8de884133be4cb909f8c982faab.

---

<a id="clinicaltrials-gov-nct00439829-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT00439829

> PeptideScanner retained ClinicalTrials.gov record NCT00439829 at 2026-11-15T22:02:39.332Z. Its registry update date was 2010-05-25, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct00439829-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2010-05-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00439829-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct00439829-cetrorelix-v1
- Content SHA-256: `10c32c95c1a7c27cb20d8476204401c5bdc136b4f214624e69c6868310bf740e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00439829 ([`ctg-observation-nct00439829-2010-05-25-b50bc906d002`](#source-ctg-observation-nct00439829-2010-05-25-b50bc906d002))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00439829 at 2026-11-15T22:02:39.332Z. Its registry update date was 2010-05-25, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct00439829-2010-05-25-b50bc906d002`](#source-ctg-observation-nct00439829-2010-05-25-b50bc906d002))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00439829 at 2026-11-15T22:02:39.332Z. Its registry update date was 2010-05-25, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct00439829-2010-05-25-b50bc906d002`](#source-ctg-observation-nct00439829-2010-05-25-b50bc906d002))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00439829-2010-05-25-b50bc906d002`](#source-ctg-observation-nct00439829-2010-05-25-b50bc906d002))

### Sources

<a id="source-ctg-observation-nct00439829-2010-05-25-b50bc906d002"></a>
- **ClinicalTrials.gov record NCT00439829 · retained source version 2010-05-25:b50bc906d002ebf47396eed30ed24c426c3bc2137b1bff29adb1b579b27182be** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00439829) (`ctg-observation-nct00439829-2010-05-25-b50bc906d002`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00439829." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct00439829-cetrorelix-v1 SHA-256: 10c32c95c1a7c27cb20d8476204401c5bdc136b4f214624e69c6868310bf740e.

---

<a id="clinicaltrials-gov-nct00628121-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT00628121

> PeptideScanner retained ClinicalTrials.gov record NCT00628121 at 2026-11-15T22:02:39.332Z. Its registry update date was 2008-03-04, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct00628121-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2008-03-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00628121-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct00628121-cetrorelix-v1
- Content SHA-256: `e2b2d04220bca5025bc5868d7fab7c7bbaa4b52b9fdc0f8f3df504858c4fad28`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00628121 ([`ctg-observation-nct00628121-2008-03-04-e779c4b7cf57`](#source-ctg-observation-nct00628121-2008-03-04-e779c4b7cf57))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00628121 at 2026-11-15T22:02:39.332Z. Its registry update date was 2008-03-04, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct00628121-2008-03-04-e779c4b7cf57`](#source-ctg-observation-nct00628121-2008-03-04-e779c4b7cf57))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00628121 at 2026-11-15T22:02:39.332Z. Its registry update date was 2008-03-04, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct00628121-2008-03-04-e779c4b7cf57`](#source-ctg-observation-nct00628121-2008-03-04-e779c4b7cf57))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00628121-2008-03-04-e779c4b7cf57`](#source-ctg-observation-nct00628121-2008-03-04-e779c4b7cf57))

### Sources

<a id="source-ctg-observation-nct00628121-2008-03-04-e779c4b7cf57"></a>
- **ClinicalTrials.gov record NCT00628121 · retained source version 2008-03-04:e779c4b7cf572f2acadfcd2ec3b54183ee1f5b3c9473cb7e8a8d1ec018f2b25e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00628121) (`ctg-observation-nct00628121-2008-03-04-e779c4b7cf57`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00628121." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct00628121-cetrorelix-v1 SHA-256: e2b2d04220bca5025bc5868d7fab7c7bbaa4b52b9fdc0f8f3df504858c4fad28.

---

<a id="clinicaltrials-gov-nct00667758-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT00667758

> PeptideScanner retained ClinicalTrials.gov record NCT00667758 at 2026-11-15T22:02:39.332Z. Its registry update date was 2012-08-06, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct00667758-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-08-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00667758-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct00667758-cetrorelix-v1
- Content SHA-256: `7f0a312c40ce25a2fd45ed72ff0c7d9a036be4c37e154d6505e8101950f0ee29`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00667758 ([`ctg-observation-nct00667758-2012-08-06-83736e9d8f97`](#source-ctg-observation-nct00667758-2012-08-06-83736e9d8f97))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00667758 at 2026-11-15T22:02:39.332Z. Its registry update date was 2012-08-06, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct00667758-2012-08-06-83736e9d8f97`](#source-ctg-observation-nct00667758-2012-08-06-83736e9d8f97))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00667758 at 2026-11-15T22:02:39.332Z. Its registry update date was 2012-08-06, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct00667758-2012-08-06-83736e9d8f97`](#source-ctg-observation-nct00667758-2012-08-06-83736e9d8f97))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00667758-2012-08-06-83736e9d8f97`](#source-ctg-observation-nct00667758-2012-08-06-83736e9d8f97))

### Sources

<a id="source-ctg-observation-nct00667758-2012-08-06-83736e9d8f97"></a>
- **ClinicalTrials.gov record NCT00667758 · retained source version 2012-08-06:83736e9d8f9705a830712040ce82a4a051538f6593847dfb0fbe83e11f9384eb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00667758) (`ctg-observation-nct00667758-2012-08-06-83736e9d8f97`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00667758." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct00667758-cetrorelix-v1 SHA-256: 7f0a312c40ce25a2fd45ed72ff0c7d9a036be4c37e154d6505e8101950f0ee29.

---

<a id="clinicaltrials-gov-nct00746031-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT00746031

> PeptideScanner retained ClinicalTrials.gov record NCT00746031 at 2026-11-15T22:02:39.332Z. Its registry update date was 2010-10-25, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct00746031-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2010-10-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00746031-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct00746031-cetrorelix-v1
- Content SHA-256: `ed97edc08905cb22c2a45df6ad1398b9017874cec282c9aa3461fbec70a6e0bf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00746031 ([`ctg-observation-nct00746031-2010-10-25-e8e7d982ac9d`](#source-ctg-observation-nct00746031-2010-10-25-e8e7d982ac9d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00746031 at 2026-11-15T22:02:39.332Z. Its registry update date was 2010-10-25, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct00746031-2010-10-25-e8e7d982ac9d`](#source-ctg-observation-nct00746031-2010-10-25-e8e7d982ac9d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00746031 at 2026-11-15T22:02:39.332Z. Its registry update date was 2010-10-25, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct00746031-2010-10-25-e8e7d982ac9d`](#source-ctg-observation-nct00746031-2010-10-25-e8e7d982ac9d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00746031-2010-10-25-e8e7d982ac9d`](#source-ctg-observation-nct00746031-2010-10-25-e8e7d982ac9d))

### Sources

<a id="source-ctg-observation-nct00746031-2010-10-25-e8e7d982ac9d"></a>
- **ClinicalTrials.gov record NCT00746031 · retained source version 2010-10-25:e8e7d982ac9d98e2514489790b8001972dd9536ab2002cd2ccb493596a41c326** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00746031) (`ctg-observation-nct00746031-2010-10-25-e8e7d982ac9d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00746031." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct00746031-cetrorelix-v1 SHA-256: ed97edc08905cb22c2a45df6ad1398b9017874cec282c9aa3461fbec70a6e0bf.

---

<a id="clinicaltrials-gov-nct01109654-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT01109654

> PeptideScanner retained ClinicalTrials.gov record NCT01109654 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-07-16, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct01109654-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-07-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01109654-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct01109654-cetrorelix-v1
- Content SHA-256: `3c1901fbdd9431a3e8eb9a89d6af4022f11ef02d720c186e26e2bfb674eca607`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01109654 ([`ctg-observation-nct01109654-2014-07-16-e08847650913`](#source-ctg-observation-nct01109654-2014-07-16-e08847650913))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01109654 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-07-16, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct01109654-2014-07-16-e08847650913`](#source-ctg-observation-nct01109654-2014-07-16-e08847650913))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01109654 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-07-16, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct01109654-2014-07-16-e08847650913`](#source-ctg-observation-nct01109654-2014-07-16-e08847650913))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01109654-2014-07-16-e08847650913`](#source-ctg-observation-nct01109654-2014-07-16-e08847650913))

### Sources

<a id="source-ctg-observation-nct01109654-2014-07-16-e08847650913"></a>
- **ClinicalTrials.gov record NCT01109654 · retained source version 2014-07-16:e088476509132bc990f0ab4967e7e993289523e837b1d289a287b84fe0485546** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01109654) (`ctg-observation-nct01109654-2014-07-16-e08847650913`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01109654." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct01109654-cetrorelix-v1 SHA-256: 3c1901fbdd9431a3e8eb9a89d6af4022f11ef02d720c186e26e2bfb674eca607.

---

<a id="clinicaltrials-gov-nct01112358-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT01112358

> PeptideScanner retained ClinicalTrials.gov record NCT01112358 at 2026-11-15T22:02:39.332Z. Its registry update date was 2018-08-28, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct01112358-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-08-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01112358-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct01112358-cetrorelix-v1
- Content SHA-256: `1e1e09bf260288157cf2a00b7b5b24f43e31da3daaf3c80628721a4421d1ffb2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01112358 ([`ctg-observation-nct01112358-2018-08-28-5f290507d998`](#source-ctg-observation-nct01112358-2018-08-28-5f290507d998))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01112358 at 2026-11-15T22:02:39.332Z. Its registry update date was 2018-08-28, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct01112358-2018-08-28-5f290507d998`](#source-ctg-observation-nct01112358-2018-08-28-5f290507d998))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01112358 at 2026-11-15T22:02:39.332Z. Its registry update date was 2018-08-28, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct01112358-2018-08-28-5f290507d998`](#source-ctg-observation-nct01112358-2018-08-28-5f290507d998))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01112358-2018-08-28-5f290507d998`](#source-ctg-observation-nct01112358-2018-08-28-5f290507d998))

### Sources

<a id="source-ctg-observation-nct01112358-2018-08-28-5f290507d998"></a>
- **ClinicalTrials.gov record NCT01112358 · retained source version 2018-08-28:5f290507d9988ed62dc090b81f8244c6ee6645d6d1a909122c4c95c3202949eb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01112358) (`ctg-observation-nct01112358-2018-08-28-5f290507d998`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01112358." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct01112358-cetrorelix-v1 SHA-256: 1e1e09bf260288157cf2a00b7b5b24f43e31da3daaf3c80628721a4421d1ffb2.

---

<a id="clinicaltrials-gov-nct01185704-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT01185704

> PeptideScanner retained ClinicalTrials.gov record NCT01185704 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-02-13, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct01185704-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-02-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01185704-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct01185704-cetrorelix-v1
- Content SHA-256: `207034d15442a4237fa2825fbdf0f8245b93f63590ce83a2a5cc19df1ed93029`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01185704 ([`ctg-observation-nct01185704-2014-02-13-bbb193d77348`](#source-ctg-observation-nct01185704-2014-02-13-bbb193d77348))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01185704 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-02-13, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct01185704-2014-02-13-bbb193d77348`](#source-ctg-observation-nct01185704-2014-02-13-bbb193d77348))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01185704 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-02-13, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct01185704-2014-02-13-bbb193d77348`](#source-ctg-observation-nct01185704-2014-02-13-bbb193d77348))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01185704-2014-02-13-bbb193d77348`](#source-ctg-observation-nct01185704-2014-02-13-bbb193d77348))

### Sources

<a id="source-ctg-observation-nct01185704-2014-02-13-bbb193d77348"></a>
- **ClinicalTrials.gov record NCT01185704 · retained source version 2014-02-13:bbb193d773483a2861f899368f56e803fcf1ecc4fefb2bef077c5149c1d57b1d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01185704) (`ctg-observation-nct01185704-2014-02-13-bbb193d77348`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01185704." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct01185704-cetrorelix-v1 SHA-256: 207034d15442a4237fa2825fbdf0f8245b93f63590ce83a2a5cc19df1ed93029.

---

<a id="clinicaltrials-gov-nct01225835-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT01225835

> PeptideScanner retained ClinicalTrials.gov record NCT01225835 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-03-14, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct01225835-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-03-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01225835-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct01225835-cetrorelix-v1
- Content SHA-256: `2bc1125bbeebdfbdd0731ebb259708ff9ef9203e20e74b732333e7c0badab0fd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01225835 ([`ctg-observation-nct01225835-2014-03-14-678b9ca14fa7`](#source-ctg-observation-nct01225835-2014-03-14-678b9ca14fa7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01225835 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-03-14, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct01225835-2014-03-14-678b9ca14fa7`](#source-ctg-observation-nct01225835-2014-03-14-678b9ca14fa7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01225835 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-03-14, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct01225835-2014-03-14-678b9ca14fa7`](#source-ctg-observation-nct01225835-2014-03-14-678b9ca14fa7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01225835-2014-03-14-678b9ca14fa7`](#source-ctg-observation-nct01225835-2014-03-14-678b9ca14fa7))

### Sources

<a id="source-ctg-observation-nct01225835-2014-03-14-678b9ca14fa7"></a>
- **ClinicalTrials.gov record NCT01225835 · retained source version 2014-03-14:678b9ca14fa79cfe83b489574851fd9994dd4aa5f1cb95c588915cf95529d607** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01225835) (`ctg-observation-nct01225835-2014-03-14-678b9ca14fa7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01225835." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct01225835-cetrorelix-v1 SHA-256: 2bc1125bbeebdfbdd0731ebb259708ff9ef9203e20e74b732333e7c0badab0fd.

---

<a id="clinicaltrials-gov-nct01402336-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT01402336

> PeptideScanner retained ClinicalTrials.gov record NCT01402336 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-10-10, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct01402336-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-10-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01402336-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct01402336-cetrorelix-v1
- Content SHA-256: `6bf792518085d500a7be7efec4b6865d77a22f9c36e053b9185b94d46fd698b8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01402336 ([`ctg-observation-nct01402336-2017-10-10-43890aa15820`](#source-ctg-observation-nct01402336-2017-10-10-43890aa15820))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01402336 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-10-10, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct01402336-2017-10-10-43890aa15820`](#source-ctg-observation-nct01402336-2017-10-10-43890aa15820))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01402336 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-10-10, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct01402336-2017-10-10-43890aa15820`](#source-ctg-observation-nct01402336-2017-10-10-43890aa15820))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01402336-2017-10-10-43890aa15820`](#source-ctg-observation-nct01402336-2017-10-10-43890aa15820))

### Sources

<a id="source-ctg-observation-nct01402336-2017-10-10-43890aa15820"></a>
- **ClinicalTrials.gov record NCT01402336 · retained source version 2017-10-10:43890aa15820ea3954d6ba838bc2c02337b7d7d8b6eebd52e9d89caa208a661c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01402336) (`ctg-observation-nct01402336-2017-10-10-43890aa15820`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01402336." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct01402336-cetrorelix-v1 SHA-256: 6bf792518085d500a7be7efec4b6865d77a22f9c36e053b9185b94d46fd698b8.

---

<a id="clinicaltrials-gov-nct01457703-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT01457703

> PeptideScanner retained ClinicalTrials.gov record NCT01457703 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-01-12, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct01457703-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01457703-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct01457703-cetrorelix-v1
- Content SHA-256: `c9e40abcbcd16d65cf010d70d8d33b0def31ca9fdc75fb2a11e11c3dcd3d435b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01457703 ([`ctg-observation-nct01457703-2017-01-12-27d7f964cbe7`](#source-ctg-observation-nct01457703-2017-01-12-27d7f964cbe7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01457703 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-01-12, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct01457703-2017-01-12-27d7f964cbe7`](#source-ctg-observation-nct01457703-2017-01-12-27d7f964cbe7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01457703 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-01-12, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct01457703-2017-01-12-27d7f964cbe7`](#source-ctg-observation-nct01457703-2017-01-12-27d7f964cbe7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01457703-2017-01-12-27d7f964cbe7`](#source-ctg-observation-nct01457703-2017-01-12-27d7f964cbe7))

### Sources

<a id="source-ctg-observation-nct01457703-2017-01-12-27d7f964cbe7"></a>
- **ClinicalTrials.gov record NCT01457703 · retained source version 2017-01-12:27d7f964cbe7d2d5c145c543f4b68998742bfe59770098081e8b4da1c6a4c4e7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01457703) (`ctg-observation-nct01457703-2017-01-12-27d7f964cbe7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01457703." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct01457703-cetrorelix-v1 SHA-256: c9e40abcbcd16d65cf010d70d8d33b0def31ca9fdc75fb2a11e11c3dcd3d435b.

---

<a id="clinicaltrials-gov-nct01565265-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT01565265

> PeptideScanner retained ClinicalTrials.gov record NCT01565265 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-05-01, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct01565265-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-05-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01565265-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct01565265-cetrorelix-v1
- Content SHA-256: `368e60cc0e01a69e55534539ec75951e19b88e98abce108a5eb4a16fb979839a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01565265 ([`ctg-observation-nct01565265-2017-05-01-bfc63e3eb690`](#source-ctg-observation-nct01565265-2017-05-01-bfc63e3eb690))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01565265 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-05-01, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct01565265-2017-05-01-bfc63e3eb690`](#source-ctg-observation-nct01565265-2017-05-01-bfc63e3eb690))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01565265 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-05-01, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct01565265-2017-05-01-bfc63e3eb690`](#source-ctg-observation-nct01565265-2017-05-01-bfc63e3eb690))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01565265-2017-05-01-bfc63e3eb690`](#source-ctg-observation-nct01565265-2017-05-01-bfc63e3eb690))

### Sources

<a id="source-ctg-observation-nct01565265-2017-05-01-bfc63e3eb690"></a>
- **ClinicalTrials.gov record NCT01565265 · retained source version 2017-05-01:bfc63e3eb6906e7d8e9d456f3a5f254a0a33e86a3c1f8708602b5e3a55366305** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01565265) (`ctg-observation-nct01565265-2017-05-01-bfc63e3eb690`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01565265." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct01565265-cetrorelix-v1 SHA-256: 368e60cc0e01a69e55534539ec75951e19b88e98abce108a5eb4a16fb979839a.

---

<a id="clinicaltrials-gov-nct02042196-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT02042196

> PeptideScanner retained ClinicalTrials.gov record NCT02042196 at 2026-11-15T22:02:39.332Z. Its registry update date was 2019-07-11, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct02042196-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-07-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02042196-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct02042196-cetrorelix-v1
- Content SHA-256: `c19ea639d4b9d7e13cb13f7dcbb1ce5ba2339ce391e4768aafb9c9f3c40efa06`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02042196 ([`ctg-observation-nct02042196-2019-07-11-4a4a4c96b82d`](#source-ctg-observation-nct02042196-2019-07-11-4a4a4c96b82d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02042196 at 2026-11-15T22:02:39.332Z. Its registry update date was 2019-07-11, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct02042196-2019-07-11-4a4a4c96b82d`](#source-ctg-observation-nct02042196-2019-07-11-4a4a4c96b82d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02042196 at 2026-11-15T22:02:39.332Z. Its registry update date was 2019-07-11, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct02042196-2019-07-11-4a4a4c96b82d`](#source-ctg-observation-nct02042196-2019-07-11-4a4a4c96b82d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02042196-2019-07-11-4a4a4c96b82d`](#source-ctg-observation-nct02042196-2019-07-11-4a4a4c96b82d))

### Sources

<a id="source-ctg-observation-nct02042196-2019-07-11-4a4a4c96b82d"></a>
- **ClinicalTrials.gov record NCT02042196 · retained source version 2019-07-11:4a4a4c96b82db0fc2a4bdbcf5433d62ea7797f2bad99938a542eabdd5522ce51** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02042196) (`ctg-observation-nct02042196-2019-07-11-4a4a4c96b82d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02042196." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct02042196-cetrorelix-v1 SHA-256: c19ea639d4b9d7e13cb13f7dcbb1ce5ba2339ce391e4768aafb9c9f3c40efa06.

---

<a id="clinicaltrials-gov-nct02333253-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT02333253

> PeptideScanner retained ClinicalTrials.gov record NCT02333253 at 2026-11-15T22:02:39.332Z. Its registry update date was 2016-01-27, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct02333253-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02333253-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct02333253-cetrorelix-v1
- Content SHA-256: `8be4d8118dbca56a7dc470f5bace45c98752761c0937e12f46f80b615cc2d928`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02333253 ([`ctg-observation-nct02333253-2016-01-27-e368f7e3ba0f`](#source-ctg-observation-nct02333253-2016-01-27-e368f7e3ba0f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02333253 at 2026-11-15T22:02:39.332Z. Its registry update date was 2016-01-27, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct02333253-2016-01-27-e368f7e3ba0f`](#source-ctg-observation-nct02333253-2016-01-27-e368f7e3ba0f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02333253 at 2026-11-15T22:02:39.332Z. Its registry update date was 2016-01-27, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct02333253-2016-01-27-e368f7e3ba0f`](#source-ctg-observation-nct02333253-2016-01-27-e368f7e3ba0f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02333253-2016-01-27-e368f7e3ba0f`](#source-ctg-observation-nct02333253-2016-01-27-e368f7e3ba0f))

### Sources

<a id="source-ctg-observation-nct02333253-2016-01-27-e368f7e3ba0f"></a>
- **ClinicalTrials.gov record NCT02333253 · retained source version 2016-01-27:e368f7e3ba0f9a2866da6ebfe51bd884de830ccaebc1d666fa50c3a934832b0b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02333253) (`ctg-observation-nct02333253-2016-01-27-e368f7e3ba0f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02333253." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct02333253-cetrorelix-v1 SHA-256: 8be4d8118dbca56a7dc470f5bace45c98752761c0937e12f46f80b615cc2d928.

---

<a id="clinicaltrials-gov-nct02640976-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT02640976

> PeptideScanner retained ClinicalTrials.gov record NCT02640976 at 2026-11-15T22:02:39.332Z. Its registry update date was 2015-12-29, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct02640976-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-12-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02640976-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct02640976-cetrorelix-v1
- Content SHA-256: `62c311dc9a4e6a2675b9dfaa9876527768adc7589b9d7c8d5836718a3c3720a0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02640976 ([`ctg-observation-nct02640976-2015-12-29-e901c63d0c74`](#source-ctg-observation-nct02640976-2015-12-29-e901c63d0c74))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02640976 at 2026-11-15T22:02:39.332Z. Its registry update date was 2015-12-29, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct02640976-2015-12-29-e901c63d0c74`](#source-ctg-observation-nct02640976-2015-12-29-e901c63d0c74))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02640976 at 2026-11-15T22:02:39.332Z. Its registry update date was 2015-12-29, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct02640976-2015-12-29-e901c63d0c74`](#source-ctg-observation-nct02640976-2015-12-29-e901c63d0c74))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02640976-2015-12-29-e901c63d0c74`](#source-ctg-observation-nct02640976-2015-12-29-e901c63d0c74))

### Sources

<a id="source-ctg-observation-nct02640976-2015-12-29-e901c63d0c74"></a>
- **ClinicalTrials.gov record NCT02640976 · retained source version 2015-12-29:e901c63d0c74aec599e531c5de7400e81814d110412f6a3556f7c07c2f38246e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02640976) (`ctg-observation-nct02640976-2015-12-29-e901c63d0c74`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02640976." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct02640976-cetrorelix-v1 SHA-256: 62c311dc9a4e6a2675b9dfaa9876527768adc7589b9d7c8d5836718a3c3720a0.

---

<a id="clinicaltrials-gov-nct02784457-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT02784457

> PeptideScanner retained ClinicalTrials.gov record NCT02784457 at 2026-11-15T22:02:39.332Z. Its registry update date was 2016-05-27, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct02784457-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-05-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02784457-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct02784457-cetrorelix-v1
- Content SHA-256: `cfc4651a64b750e378166c5a906367b2b7e7e886396842ff85b0f58a4a537ad3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02784457 ([`ctg-observation-nct02784457-2016-05-27-adf7627dfe69`](#source-ctg-observation-nct02784457-2016-05-27-adf7627dfe69))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02784457 at 2026-11-15T22:02:39.332Z. Its registry update date was 2016-05-27, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct02784457-2016-05-27-adf7627dfe69`](#source-ctg-observation-nct02784457-2016-05-27-adf7627dfe69))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02784457 at 2026-11-15T22:02:39.332Z. Its registry update date was 2016-05-27, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct02784457-2016-05-27-adf7627dfe69`](#source-ctg-observation-nct02784457-2016-05-27-adf7627dfe69))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02784457-2016-05-27-adf7627dfe69`](#source-ctg-observation-nct02784457-2016-05-27-adf7627dfe69))

### Sources

<a id="source-ctg-observation-nct02784457-2016-05-27-adf7627dfe69"></a>
- **ClinicalTrials.gov record NCT02784457 · retained source version 2016-05-27:adf7627dfe6949cecc772f15d502dba3bbf2537d1d1c276f9ed5defce2d1739e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02784457) (`ctg-observation-nct02784457-2016-05-27-adf7627dfe69`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02784457." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct02784457-cetrorelix-v1 SHA-256: cfc4651a64b750e378166c5a906367b2b7e7e886396842ff85b0f58a4a537ad3.

---

<a id="clinicaltrials-gov-nct02892942-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT02892942

> PeptideScanner retained ClinicalTrials.gov record NCT02892942 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct02892942-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02892942-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct02892942-cetrorelix-v1
- Content SHA-256: `52ba0ec7a6a915e8c2d58207fa978b4b85fab3bfcdf462010e3af763ac4e919a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02892942 ([`ctg-observation-nct02892942-2026-04-03-f0fdc955933e`](#source-ctg-observation-nct02892942-2026-04-03-f0fdc955933e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02892942 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct02892942-2026-04-03-f0fdc955933e`](#source-ctg-observation-nct02892942-2026-04-03-f0fdc955933e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02892942 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct02892942-2026-04-03-f0fdc955933e`](#source-ctg-observation-nct02892942-2026-04-03-f0fdc955933e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02892942-2026-04-03-f0fdc955933e`](#source-ctg-observation-nct02892942-2026-04-03-f0fdc955933e))

### Sources

<a id="source-ctg-observation-nct02892942-2026-04-03-f0fdc955933e"></a>
- **ClinicalTrials.gov record NCT02892942 · retained source version 2026-04-03:f0fdc955933e861035a055cc5950f3e33a0eae46b95c8fc6423b0ddaa7754ace** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02892942) (`ctg-observation-nct02892942-2026-04-03-f0fdc955933e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02892942." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct02892942-cetrorelix-v1 SHA-256: 52ba0ec7a6a915e8c2d58207fa978b4b85fab3bfcdf462010e3af763ac4e919a.

---

<a id="clinicaltrials-gov-nct03291821-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT03291821

> PeptideScanner retained ClinicalTrials.gov record NCT03291821 at 2026-11-15T22:02:39.332Z. Its registry update date was 2020-12-29, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct03291821-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-12-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03291821-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct03291821-cetrorelix-v1
- Content SHA-256: `08de501177a36921b7f16a77e9c564da072ee366af80b342ba29d2b156a68576`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03291821 ([`ctg-observation-nct03291821-2020-12-29-bd3db008f464`](#source-ctg-observation-nct03291821-2020-12-29-bd3db008f464))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03291821 at 2026-11-15T22:02:39.332Z. Its registry update date was 2020-12-29, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct03291821-2020-12-29-bd3db008f464`](#source-ctg-observation-nct03291821-2020-12-29-bd3db008f464))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03291821 at 2026-11-15T22:02:39.332Z. Its registry update date was 2020-12-29, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct03291821-2020-12-29-bd3db008f464`](#source-ctg-observation-nct03291821-2020-12-29-bd3db008f464))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03291821-2020-12-29-bd3db008f464`](#source-ctg-observation-nct03291821-2020-12-29-bd3db008f464))

### Sources

<a id="source-ctg-observation-nct03291821-2020-12-29-bd3db008f464"></a>
- **ClinicalTrials.gov record NCT03291821 · retained source version 2020-12-29:bd3db008f464b02c3e9ea57ab59cd32d54e39aaae329cbe5417d13b241de0b43** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03291821) (`ctg-observation-nct03291821-2020-12-29-bd3db008f464`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03291821." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct03291821-cetrorelix-v1 SHA-256: 08de501177a36921b7f16a77e9c564da072ee366af80b342ba29d2b156a68576.

---

<a id="clinicaltrials-gov-nct03759301-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT03759301

> PeptideScanner retained ClinicalTrials.gov record NCT03759301 at 2026-11-15T22:02:39.332Z. Its registry update date was 2019-06-24, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct03759301-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-06-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03759301-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct03759301-cetrorelix-v1
- Content SHA-256: `e04155df1a0dea4962e78dd147c61403368cb7e634fa464e08bc68e03e047448`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03759301 ([`ctg-observation-nct03759301-2019-06-24-7bbd64c9c195`](#source-ctg-observation-nct03759301-2019-06-24-7bbd64c9c195))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03759301 at 2026-11-15T22:02:39.332Z. Its registry update date was 2019-06-24, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct03759301-2019-06-24-7bbd64c9c195`](#source-ctg-observation-nct03759301-2019-06-24-7bbd64c9c195))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03759301 at 2026-11-15T22:02:39.332Z. Its registry update date was 2019-06-24, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct03759301-2019-06-24-7bbd64c9c195`](#source-ctg-observation-nct03759301-2019-06-24-7bbd64c9c195))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03759301-2019-06-24-7bbd64c9c195`](#source-ctg-observation-nct03759301-2019-06-24-7bbd64c9c195))

### Sources

<a id="source-ctg-observation-nct03759301-2019-06-24-7bbd64c9c195"></a>
- **ClinicalTrials.gov record NCT03759301 · retained source version 2019-06-24:7bbd64c9c195f9e541310ba1196370c5b94032b7958ca8e24576ba84bccc0ce3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03759301) (`ctg-observation-nct03759301-2019-06-24-7bbd64c9c195`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03759301." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct03759301-cetrorelix-v1 SHA-256: e04155df1a0dea4962e78dd147c61403368cb7e634fa464e08bc68e03e047448.

---

<a id="clinicaltrials-gov-nct04414748-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT04414748

> PeptideScanner retained ClinicalTrials.gov record NCT04414748 at 2026-11-15T22:02:39.332Z. Its registry update date was 2025-05-31, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct04414748-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-05-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04414748-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct04414748-cetrorelix-v1
- Content SHA-256: `6e04d79bcd0ebeda5a06f1e344ce65e1c06661ddc00b615245a12e8661b956c9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04414748 ([`ctg-observation-nct04414748-2025-05-31-abc01f8dbe4b`](#source-ctg-observation-nct04414748-2025-05-31-abc01f8dbe4b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04414748 at 2026-11-15T22:02:39.332Z. Its registry update date was 2025-05-31, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct04414748-2025-05-31-abc01f8dbe4b`](#source-ctg-observation-nct04414748-2025-05-31-abc01f8dbe4b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04414748 at 2026-11-15T22:02:39.332Z. Its registry update date was 2025-05-31, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct04414748-2025-05-31-abc01f8dbe4b`](#source-ctg-observation-nct04414748-2025-05-31-abc01f8dbe4b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04414748-2025-05-31-abc01f8dbe4b`](#source-ctg-observation-nct04414748-2025-05-31-abc01f8dbe4b))

### Sources

<a id="source-ctg-observation-nct04414748-2025-05-31-abc01f8dbe4b"></a>
- **ClinicalTrials.gov record NCT04414748 · retained source version 2025-05-31:abc01f8dbe4ba938d295042c42438959239bf6f5bc1ca46b71214d5bcb75515f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04414748) (`ctg-observation-nct04414748-2025-05-31-abc01f8dbe4b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04414748." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct04414748-cetrorelix-v1 SHA-256: 6e04d79bcd0ebeda5a06f1e344ce65e1c06661ddc00b615245a12e8661b956c9.

---

<a id="clinicaltrials-gov-nct04418908-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT04418908

> PeptideScanner retained ClinicalTrials.gov record NCT04418908 at 2026-11-15T22:02:39.332Z. Its registry update date was 2020-06-05, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct04418908-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-06-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04418908-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct04418908-cetrorelix-v1
- Content SHA-256: `1bdb1830d44c6f986b26524ec9febdeba21f02fc1e93e2627d841ff38f426156`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04418908 ([`ctg-observation-nct04418908-2020-06-05-8b586fdc3700`](#source-ctg-observation-nct04418908-2020-06-05-8b586fdc3700))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04418908 at 2026-11-15T22:02:39.332Z. Its registry update date was 2020-06-05, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct04418908-2020-06-05-8b586fdc3700`](#source-ctg-observation-nct04418908-2020-06-05-8b586fdc3700))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04418908 at 2026-11-15T22:02:39.332Z. Its registry update date was 2020-06-05, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct04418908-2020-06-05-8b586fdc3700`](#source-ctg-observation-nct04418908-2020-06-05-8b586fdc3700))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04418908-2020-06-05-8b586fdc3700`](#source-ctg-observation-nct04418908-2020-06-05-8b586fdc3700))

### Sources

<a id="source-ctg-observation-nct04418908-2020-06-05-8b586fdc3700"></a>
- **ClinicalTrials.gov record NCT04418908 · retained source version 2020-06-05:8b586fdc37001c54542dc6d444b5808b16ecb7784df9ab572e9fbc6a44cd086c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04418908) (`ctg-observation-nct04418908-2020-06-05-8b586fdc3700`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04418908." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct04418908-cetrorelix-v1 SHA-256: 1bdb1830d44c6f986b26524ec9febdeba21f02fc1e93e2627d841ff38f426156.

---

<a id="clinicaltrials-gov-nct05326087-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT05326087

> PeptideScanner retained ClinicalTrials.gov record NCT05326087 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct05326087-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05326087-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct05326087-cetrorelix-v1
- Content SHA-256: `477907b1a1aca021207a7238aee6c4a6b2a41a58c206cd8699f94a0ef1d6e9ae`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05326087 ([`ctg-observation-nct05326087-2026-11-09-50e9703739f0`](#source-ctg-observation-nct05326087-2026-11-09-50e9703739f0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05326087 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct05326087-2026-11-09-50e9703739f0`](#source-ctg-observation-nct05326087-2026-11-09-50e9703739f0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05326087 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct05326087-2026-11-09-50e9703739f0`](#source-ctg-observation-nct05326087-2026-11-09-50e9703739f0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05326087-2026-11-09-50e9703739f0`](#source-ctg-observation-nct05326087-2026-11-09-50e9703739f0))

### Sources

<a id="source-ctg-observation-nct05326087-2026-11-09-50e9703739f0"></a>
- **ClinicalTrials.gov record NCT05326087 · retained source version 2026-11-09:50e9703739f0e2e13e89279376922057af38ffc8dbc6af39facfba1e162fbabc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05326087) (`ctg-observation-nct05326087-2026-11-09-50e9703739f0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05326087." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct05326087-cetrorelix-v1 SHA-256: 477907b1a1aca021207a7238aee6c4a6b2a41a58c206cd8699f94a0ef1d6e9ae.

---

<a id="clinicaltrials-gov-nct05767086-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT05767086

> PeptideScanner retained ClinicalTrials.gov record NCT05767086 at 2026-11-15T22:02:39.332Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct05767086-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-10-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05767086-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct05767086-cetrorelix-v1
- Content SHA-256: `9e13bb2033c8c9e18cc83a6bbc62e3ff91d1cb3b9c39b533e234c5fe92355780`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05767086 ([`ctg-observation-nct05767086-2024-10-15-fdb8ddef011b`](#source-ctg-observation-nct05767086-2024-10-15-fdb8ddef011b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05767086 at 2026-11-15T22:02:39.332Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct05767086-2024-10-15-fdb8ddef011b`](#source-ctg-observation-nct05767086-2024-10-15-fdb8ddef011b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05767086 at 2026-11-15T22:02:39.332Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct05767086-2024-10-15-fdb8ddef011b`](#source-ctg-observation-nct05767086-2024-10-15-fdb8ddef011b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05767086-2024-10-15-fdb8ddef011b`](#source-ctg-observation-nct05767086-2024-10-15-fdb8ddef011b))

### Sources

<a id="source-ctg-observation-nct05767086-2024-10-15-fdb8ddef011b"></a>
- **ClinicalTrials.gov record NCT05767086 · retained source version 2024-10-15:fdb8ddef011bd8a71e58b83bc25bd1496984e7cfdbf583f505f927add014982f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05767086) (`ctg-observation-nct05767086-2024-10-15-fdb8ddef011b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05767086." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct05767086-cetrorelix-v1 SHA-256: 9e13bb2033c8c9e18cc83a6bbc62e3ff91d1cb3b9c39b533e234c5fe92355780.

---

<a id="clinicaltrials-gov-nct05951400-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT05951400

> PeptideScanner retained ClinicalTrials.gov record NCT05951400 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-04-15, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct05951400-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05951400-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct05951400-cetrorelix-v1
- Content SHA-256: `05eefd0268c76e8543524b64eb9cab6247d3bfc5058fe48715dc39c7865210cf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05951400 ([`ctg-observation-nct05951400-2026-04-15-486896aa9f5a`](#source-ctg-observation-nct05951400-2026-04-15-486896aa9f5a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05951400 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-04-15, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct05951400-2026-04-15-486896aa9f5a`](#source-ctg-observation-nct05951400-2026-04-15-486896aa9f5a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05951400 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-04-15, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct05951400-2026-04-15-486896aa9f5a`](#source-ctg-observation-nct05951400-2026-04-15-486896aa9f5a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05951400-2026-04-15-486896aa9f5a`](#source-ctg-observation-nct05951400-2026-04-15-486896aa9f5a))

### Sources

<a id="source-ctg-observation-nct05951400-2026-04-15-486896aa9f5a"></a>
- **ClinicalTrials.gov record NCT05951400 · retained source version 2026-04-15:486896aa9f5aeec50e4baca694a5e851f70843afe2e595c5e28732b53ccae072** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05951400) (`ctg-observation-nct05951400-2026-04-15-486896aa9f5a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05951400." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct05951400-cetrorelix-v1 SHA-256: 05eefd0268c76e8543524b64eb9cab6247d3bfc5058fe48715dc39c7865210cf.

---

<a id="clinicaltrials-gov-nct06378268-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT06378268

> PeptideScanner retained ClinicalTrials.gov record NCT06378268 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct06378268-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06378268-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct06378268-cetrorelix-v1
- Content SHA-256: `733ad73f34a26e02645909709648d1db2a523e9cfaf0b1e1567f5c03941ee1b7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06378268 ([`ctg-observation-nct06378268-2026-03-20-91277c88fd3a`](#source-ctg-observation-nct06378268-2026-03-20-91277c88fd3a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06378268 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct06378268-2026-03-20-91277c88fd3a`](#source-ctg-observation-nct06378268-2026-03-20-91277c88fd3a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06378268 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct06378268-2026-03-20-91277c88fd3a`](#source-ctg-observation-nct06378268-2026-03-20-91277c88fd3a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06378268-2026-03-20-91277c88fd3a`](#source-ctg-observation-nct06378268-2026-03-20-91277c88fd3a))

### Sources

<a id="source-ctg-observation-nct06378268-2026-03-20-91277c88fd3a"></a>
- **ClinicalTrials.gov record NCT06378268 · retained source version 2026-03-20:91277c88fd3a22a52bb7b0e975e599cdefec4b8412399c28e43c6d1edbbecb74** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06378268) (`ctg-observation-nct06378268-2026-03-20-91277c88fd3a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06378268." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct06378268-cetrorelix-v1 SHA-256: 733ad73f34a26e02645909709648d1db2a523e9cfaf0b1e1567f5c03941ee1b7.

---

<a id="clinicaltrials-gov-nct06608186-cetrorelix-v1"></a>

## ClinicalTrials.gov record NCT06608186

> PeptideScanner retained ClinicalTrials.gov record NCT06608186 at 2026-11-15T22:02:39.332Z. Its registry update date was 2025-01-22, and PeptideScanner's reviewed identity mapping was cetrorelix.

- Evidence object: `story:clinicaltrials-gov-nct06608186-cetrorelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-01-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06608186-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct06608186-cetrorelix-v1
- Content SHA-256: `102bb8d0bdd1cca8bc5312cb624a4f9c9c38b55db6cfcfa3645a20b2adc93465`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06608186 ([`ctg-observation-nct06608186-2025-01-22-b2d9c0ee0bbe`](#source-ctg-observation-nct06608186-2025-01-22-b2d9c0ee0bbe))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06608186 at 2026-11-15T22:02:39.332Z. Its registry update date was 2025-01-22, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct06608186-2025-01-22-b2d9c0ee0bbe`](#source-ctg-observation-nct06608186-2025-01-22-b2d9c0ee0bbe))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06608186 at 2026-11-15T22:02:39.332Z. Its registry update date was 2025-01-22, and PeptideScanner's reviewed identity mapping was cetrorelix. ([`ctg-observation-nct06608186-2025-01-22-b2d9c0ee0bbe`](#source-ctg-observation-nct06608186-2025-01-22-b2d9c0ee0bbe))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06608186-2025-01-22-b2d9c0ee0bbe`](#source-ctg-observation-nct06608186-2025-01-22-b2d9c0ee0bbe))

### Sources

<a id="source-ctg-observation-nct06608186-2025-01-22-b2d9c0ee0bbe"></a>
- **ClinicalTrials.gov record NCT06608186 · retained source version 2025-01-22:b2d9c0ee0bbe43b20cff4d61a48d699444aab98edb991859ada56a0c809c592b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06608186) (`ctg-observation-nct06608186-2025-01-22-b2d9c0ee0bbe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06608186." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#clinicaltrials-gov-nct06608186-cetrorelix-v1 SHA-256: 102bb8d0bdd1cca8bc5312cb624a4f9c9c38b55db6cfcfa3645a20b2adc93465.

---

<a id="fda-drugs-anda214540-v1"></a>

## Drugs@FDA application ANDA214540

> The official Drugs@FDA dataset lists original submission 1 for ANDA 214540 with status AP dated 2024-04-24, and names cetrorelix acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda214540:v1`
- Evidence domain: Regulatory
- Date in source: 2024-04-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda214540/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#fda-drugs-anda214540-v1
- Content SHA-256: `57d80efc1f25d5d86ee38410de50e18b8cb14437458e54bc37a5ba66f7b92929`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA214540 ([`fda-drugs-anda214540-2024-04-24-260d14aaa44b`](#source-fda-drugs-anda214540-2024-04-24-260d14aaa44b))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 214540 with status AP dated 2024-04-24, and names cetrorelix acetate among the application record's active ingredients. ([`fda-drugs-anda214540-2024-04-24-260d14aaa44b`](#source-fda-drugs-anda214540-2024-04-24-260d14aaa44b))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 214540 with status AP dated 2024-04-24, and names cetrorelix acetate among the application record's active ingredients. ([`fda-drugs-anda214540-2024-04-24-260d14aaa44b`](#source-fda-drugs-anda214540-2024-04-24-260d14aaa44b))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda214540-2024-04-24-260d14aaa44b`](#source-fda-drugs-anda214540-2024-04-24-260d14aaa44b))

### Sources

<a id="source-fda-drugs-anda214540-2024-04-24-260d14aaa44b"></a>
- **Drugs@FDA application ANDA214540 · original submission status AP · 2024-04-24 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA214540%22&limit=1) (`fda-drugs-anda214540-2024-04-24-260d14aaa44b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA214540." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#fda-drugs-anda214540-v1 SHA-256: 57d80efc1f25d5d86ee38410de50e18b8cb14437458e54bc37a5ba66f7b92929.

---

<a id="fda-drugs-anda215737-v1"></a>

## Drugs@FDA application ANDA215737

> The official Drugs@FDA dataset lists original submission 1 for ANDA 215737 with status AP dated 2022-08-12, and names cetrorelix acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda215737:v1`
- Evidence domain: Regulatory
- Date in source: 2022-08-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda215737/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#fda-drugs-anda215737-v1
- Content SHA-256: `b0ca8ae07c01b43f885b094801b8ea564d02f399a2a77b788bdd33f3b09217db`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA215737 ([`fda-drugs-anda215737-2022-08-12-f50b357343c0`](#source-fda-drugs-anda215737-2022-08-12-f50b357343c0))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 215737 with status AP dated 2022-08-12, and names cetrorelix acetate among the application record's active ingredients. ([`fda-drugs-anda215737-2022-08-12-f50b357343c0`](#source-fda-drugs-anda215737-2022-08-12-f50b357343c0))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 215737 with status AP dated 2022-08-12, and names cetrorelix acetate among the application record's active ingredients. ([`fda-drugs-anda215737-2022-08-12-f50b357343c0`](#source-fda-drugs-anda215737-2022-08-12-f50b357343c0))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda215737-2022-08-12-f50b357343c0`](#source-fda-drugs-anda215737-2022-08-12-f50b357343c0))

### Sources

<a id="source-fda-drugs-anda215737-2022-08-12-f50b357343c0"></a>
- **Drugs@FDA application ANDA215737 · original submission status AP · 2022-08-12 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA215737%22&limit=1) (`fda-drugs-anda215737-2022-08-12-f50b357343c0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA215737." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#fda-drugs-anda215737-v1 SHA-256: b0ca8ae07c01b43f885b094801b8ea564d02f399a2a77b788bdd33f3b09217db.

---

<a id="fda-drugs-anda217776-v1"></a>

## Drugs@FDA application ANDA217776

> The official Drugs@FDA dataset lists original submission 1 for ANDA 217776 with status AP dated 2024-04-16, and names cetrorelix acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda217776:v1`
- Evidence domain: Regulatory
- Date in source: 2024-04-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda217776/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#fda-drugs-anda217776-v1
- Content SHA-256: `dd5db47a53849b14a891dd45f9f8433db519fb0651631eff92fb50c5fec578dd`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA217776 ([`fda-drugs-anda217776-2024-04-16-267b9bd0ca23`](#source-fda-drugs-anda217776-2024-04-16-267b9bd0ca23))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 217776 with status AP dated 2024-04-16, and names cetrorelix acetate among the application record's active ingredients. ([`fda-drugs-anda217776-2024-04-16-267b9bd0ca23`](#source-fda-drugs-anda217776-2024-04-16-267b9bd0ca23))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 217776 with status AP dated 2024-04-16, and names cetrorelix acetate among the application record's active ingredients. ([`fda-drugs-anda217776-2024-04-16-267b9bd0ca23`](#source-fda-drugs-anda217776-2024-04-16-267b9bd0ca23))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda217776-2024-04-16-267b9bd0ca23`](#source-fda-drugs-anda217776-2024-04-16-267b9bd0ca23))

### Sources

<a id="source-fda-drugs-anda217776-2024-04-16-267b9bd0ca23"></a>
- **Drugs@FDA application ANDA217776 · original submission status AP · 2024-04-16 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA217776%22&limit=1) (`fda-drugs-anda217776-2024-04-16-267b9bd0ca23`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA217776." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#fda-drugs-anda217776-v1 SHA-256: dd5db47a53849b14a891dd45f9f8433db519fb0651631eff92fb50c5fec578dd.

---

<a id="fda-drugs-anda218061-v1"></a>

## Drugs@FDA application ANDA218061

> The official Drugs@FDA dataset lists original submission 1 for ANDA 218061 with status AP dated 2025-06-03, and names cetrorelix acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda218061:v1`
- Evidence domain: Regulatory
- Date in source: 2025-06-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda218061/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#fda-drugs-anda218061-v1
- Content SHA-256: `1c4194a248d7a4578c66a60a5c4f994c5a3688fe2b620db6a740d28bc3c40028`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA218061 ([`fda-drugs-anda218061-2025-06-03-dd8aa2c5bc6c`](#source-fda-drugs-anda218061-2025-06-03-dd8aa2c5bc6c))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 218061 with status AP dated 2025-06-03, and names cetrorelix acetate among the application record's active ingredients. ([`fda-drugs-anda218061-2025-06-03-dd8aa2c5bc6c`](#source-fda-drugs-anda218061-2025-06-03-dd8aa2c5bc6c))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 218061 with status AP dated 2025-06-03, and names cetrorelix acetate among the application record's active ingredients. ([`fda-drugs-anda218061-2025-06-03-dd8aa2c5bc6c`](#source-fda-drugs-anda218061-2025-06-03-dd8aa2c5bc6c))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda218061-2025-06-03-dd8aa2c5bc6c`](#source-fda-drugs-anda218061-2025-06-03-dd8aa2c5bc6c))

### Sources

<a id="source-fda-drugs-anda218061-2025-06-03-dd8aa2c5bc6c"></a>
- **Drugs@FDA application ANDA218061 · original submission status AP · 2025-06-03 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA218061%22&limit=1) (`fda-drugs-anda218061-2025-06-03-dd8aa2c5bc6c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA218061." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#fda-drugs-anda218061-v1 SHA-256: 1c4194a248d7a4578c66a60a5c4f994c5a3688fe2b620db6a740d28bc3c40028.

---

<a id="fda-drugs-anda218150-v1"></a>

## Drugs@FDA application ANDA218150

> The official Drugs@FDA dataset lists original submission 1 for ANDA 218150 with status AP dated 2024-04-25, and names cetrorelix acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda218150:v1`
- Evidence domain: Regulatory
- Date in source: 2024-04-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda218150/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#fda-drugs-anda218150-v1
- Content SHA-256: `489b27e9c13b3db8615b1d739a75f886f9d4d2c4860dc870a07867b0824ae940`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA218150 ([`fda-drugs-anda218150-2024-04-25-dbc49d9dfcd8`](#source-fda-drugs-anda218150-2024-04-25-dbc49d9dfcd8))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 218150 with status AP dated 2024-04-25, and names cetrorelix acetate among the application record's active ingredients. ([`fda-drugs-anda218150-2024-04-25-dbc49d9dfcd8`](#source-fda-drugs-anda218150-2024-04-25-dbc49d9dfcd8))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 218150 with status AP dated 2024-04-25, and names cetrorelix acetate among the application record's active ingredients. ([`fda-drugs-anda218150-2024-04-25-dbc49d9dfcd8`](#source-fda-drugs-anda218150-2024-04-25-dbc49d9dfcd8))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda218150-2024-04-25-dbc49d9dfcd8`](#source-fda-drugs-anda218150-2024-04-25-dbc49d9dfcd8))

### Sources

<a id="source-fda-drugs-anda218150-2024-04-25-dbc49d9dfcd8"></a>
- **Drugs@FDA application ANDA218150 · original submission status AP · 2024-04-25 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA218150%22&limit=1) (`fda-drugs-anda218150-2024-04-25-dbc49d9dfcd8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA218150." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#fda-drugs-anda218150-v1 SHA-256: 489b27e9c13b3db8615b1d739a75f886f9d4d2c4860dc870a07867b0824ae940.

---

<a id="fda-drugs-anda218740-v1"></a>

## Drugs@FDA application ANDA218740

> The official Drugs@FDA dataset lists original submission 1 for ANDA 218740 with status AP dated 2026-04-29, and names cetrorelix acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda218740:v1`
- Evidence domain: Regulatory
- Date in source: 2026-04-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda218740/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#fda-drugs-anda218740-v1
- Content SHA-256: `91acca2b5d62e5bb9863b477e018c5e638a985ee366dc0cdcf410da1ff315cd3`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA218740 ([`fda-drugs-anda218740-2026-04-29-62d0e87498bc`](#source-fda-drugs-anda218740-2026-04-29-62d0e87498bc))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 218740 with status AP dated 2026-04-29, and names cetrorelix acetate among the application record's active ingredients. ([`fda-drugs-anda218740-2026-04-29-62d0e87498bc`](#source-fda-drugs-anda218740-2026-04-29-62d0e87498bc))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 218740 with status AP dated 2026-04-29, and names cetrorelix acetate among the application record's active ingredients. ([`fda-drugs-anda218740-2026-04-29-62d0e87498bc`](#source-fda-drugs-anda218740-2026-04-29-62d0e87498bc))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda218740-2026-04-29-62d0e87498bc`](#source-fda-drugs-anda218740-2026-04-29-62d0e87498bc))

### Sources

<a id="source-fda-drugs-anda218740-2026-04-29-62d0e87498bc"></a>
- **Drugs@FDA application ANDA218740 · original submission status AP · 2026-04-29 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA218740%22&limit=1) (`fda-drugs-anda218740-2026-04-29-62d0e87498bc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA218740." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#fda-drugs-anda218740-v1 SHA-256: 91acca2b5d62e5bb9863b477e018c5e638a985ee366dc0cdcf410da1ff315cd3.

---

<a id="fda-drugs-nda021197-v1"></a>

## Drugs@FDA application NDA021197

> The official Drugs@FDA dataset lists original submission 1 for NDA 021197 with status AP dated 2000-08-11, and names cetrorelix acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021197:v1`
- Evidence domain: Regulatory
- Date in source: 2000-08-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021197/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#fda-drugs-nda021197-v1
- Content SHA-256: `f5a3632de865a7df89dc64d660ef8d9f05ed7d26db7f053c169cfd9f35bf04ba`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021197 ([`fda-drugs-nda021197-2000-08-11-8e088ed7fdda`](#source-fda-drugs-nda021197-2000-08-11-8e088ed7fdda))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021197 with status AP dated 2000-08-11, and names cetrorelix acetate among the application record's active ingredients. ([`fda-drugs-nda021197-2000-08-11-8e088ed7fdda`](#source-fda-drugs-nda021197-2000-08-11-8e088ed7fdda))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021197 with status AP dated 2000-08-11, and names cetrorelix acetate among the application record's active ingredients. ([`fda-drugs-nda021197-2000-08-11-8e088ed7fdda`](#source-fda-drugs-nda021197-2000-08-11-8e088ed7fdda))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021197-2000-08-11-8e088ed7fdda`](#source-fda-drugs-nda021197-2000-08-11-8e088ed7fdda))

### Sources

<a id="source-fda-drugs-nda021197-2000-08-11-8e088ed7fdda"></a>
- **Drugs@FDA application NDA021197 · original submission status AP · 2000-08-11 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021197%22&limit=1) (`fda-drugs-nda021197-2000-08-11-8e088ed7fdda`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021197." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#fda-drugs-nda021197-v1 SHA-256: f5a3632de865a7df89dc64d660ef8d9f05ed7d26db7f053c169cfd9f35bf04ba.

---

<a id="federal-register-e6-9031-v1"></a>

## Federal Register notice E6-9031

> The Federal Register published notice E6-9031, attributed to FDA and its parent HHS department, on 2006-06-09. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; CETROTIDE,” and PeptideScanner's exact reviewed identity mapping connects the document to Cetrorelix.

- Evidence object: `story:federal-register-e6-9031:v1`
- Evidence domain: Regulatory
- Date in source: 2006-06-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-e6-9031/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#federal-register-e6-9031-v1
- Content SHA-256: `7ad59fceac38898aaf2de47e8e9d9834bd645dd75ef66910633e581040c61b22`

### Claims and source pins

#### Headline

Federal Register notice E6-9031 ([`federal-register-e6-9031-20771b20df98`](#source-federal-register-e6-9031-20771b20df98))

#### Summary

The Federal Register published notice E6-9031, attributed to FDA and its parent HHS department, on 2006-06-09. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; CETROTIDE,” and PeptideScanner's exact reviewed identity mapping connects the document to Cetrorelix. ([`federal-register-e6-9031-20771b20df98`](#source-federal-register-e6-9031-20771b20df98))

#### Paragraph 1

The Federal Register published notice E6-9031, attributed to FDA and its parent HHS department, on 2006-06-09. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; CETROTIDE,” and PeptideScanner's exact reviewed identity mapping connects the document to Cetrorelix. ([`federal-register-e6-9031-20771b20df98`](#source-federal-register-e6-9031-20771b20df98))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e6-9031-20771b20df98`](#source-federal-register-e6-9031-20771b20df98))

### Sources

<a id="source-federal-register-e6-9031-20771b20df98"></a>
- **Federal Register notice E6-9031 · published 2006-06-09 · Determination of Regulatory Review Period for Purposes of Patent Extension; CETROTIDE** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2006-06-09/pdf/E6-9031.pdf) (`federal-register-e6-9031-20771b20df98`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice E6-9031." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#federal-register-e6-9031-v1 SHA-256: 7ad59fceac38898aaf2de47e8e9d9834bd645dd75ef66910633e581040c61b22.

---

<a id="pubmed-pmid-10605180-cetrorelix-v1"></a>

## \[Medical treatment of uterine fibroids with the LHRH antagonist: Cetrorelix\].

> PubMed lists PMID 10605180 in Contraception, fertilite, sexualite (1992) as Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1999-10 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-10605180-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-05-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10605180-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-10605180-cetrorelix-v1
- Content SHA-256: `48d83a89fc37c4624eef970bd0ea7a3a139ae2041ceaf74fb7e3f2f338d46c5f`

### Claims and source pins

#### Headline

\[Medical treatment of uterine fibroids with the LHRH antagonist: Cetrorelix\]. ([`pubmed-observation-pmid-10605180-2013-05-29-c6bd128f891a`](#source-pubmed-observation-pmid-10605180-2013-05-29-c6bd128f891a))

#### Summary

PubMed lists PMID 10605180 in Contraception, fertilite, sexualite (1992) as Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1999-10 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10605180-2013-05-29-c6bd128f891a`](#source-pubmed-observation-pmid-10605180-2013-05-29-c6bd128f891a))

#### Paragraph 1

PubMed lists PMID 10605180 in Contraception, fertilite, sexualite (1992) as Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1999-10 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10605180-2013-05-29-c6bd128f891a`](#source-pubmed-observation-pmid-10605180-2013-05-29-c6bd128f891a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10605180-2013-05-29-c6bd128f891a`](#source-pubmed-observation-pmid-10605180-2013-05-29-c6bd128f891a))

### Sources

<a id="source-pubmed-observation-pmid-10605180-2013-05-29-c6bd128f891a"></a>
- **\[Medical treatment of uterine fibroids with the LHRH antagonist: Cetrorelix\]. · retained source version 1:2013-05-29:current:c6bd128f891a448d8a150e67fdb5a1872fe71b75df0368e76fb4d6252105798c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10605180/) (`pubmed-observation-pmid-10605180-2013-05-29-c6bd128f891a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Medical treatment of uterine fibroids with the LHRH antagonist: Cetrorelix\]." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-10605180-cetrorelix-v1 SHA-256: 48d83a89fc37c4624eef970bd0ea7a3a139ae2041ceaf74fb7e3f2f338d46c5f.

---

<a id="pubmed-pmid-10972520-cetrorelix-v1"></a>

## The LHRH antagonist cetrorelix: a review.

> PubMed lists PMID 10972520 in Human reproduction update as Journal Article, Review, with publication-date metadata of 2000 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-10972520-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-05-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10972520-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-10972520-cetrorelix-v1
- Content SHA-256: `166e57e7bd03aad465835b2fa6563ad61c79d4bd7414f9ca2d28006e9d15ef51`

### Claims and source pins

#### Headline

The LHRH antagonist cetrorelix: a review. ([`pubmed-observation-pmid-10972520-2019-05-13-30bc4d53d0f7`](#source-pubmed-observation-pmid-10972520-2019-05-13-30bc4d53d0f7))

#### Summary

PubMed lists PMID 10972520 in Human reproduction update as Journal Article, Review, with publication-date metadata of 2000 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10972520-2019-05-13-30bc4d53d0f7`](#source-pubmed-observation-pmid-10972520-2019-05-13-30bc4d53d0f7))

#### Paragraph 1

PubMed lists PMID 10972520 in Human reproduction update as Journal Article, Review, with publication-date metadata of 2000 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10972520-2019-05-13-30bc4d53d0f7`](#source-pubmed-observation-pmid-10972520-2019-05-13-30bc4d53d0f7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10972520-2019-05-13-30bc4d53d0f7`](#source-pubmed-observation-pmid-10972520-2019-05-13-30bc4d53d0f7))

### Sources

<a id="source-pubmed-observation-pmid-10972520-2019-05-13-30bc4d53d0f7"></a>
- **The LHRH antagonist cetrorelix: a review. · retained source version 1:2019-05-13:current:30bc4d53d0f71b22aeabb14dd7b2364d7943fb66c791c4c7214f4e3d516eb011** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10972520/) (`pubmed-observation-pmid-10972520-2019-05-13-30bc4d53d0f7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The LHRH antagonist cetrorelix: a review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-10972520-cetrorelix-v1 SHA-256: 166e57e7bd03aad465835b2fa6563ad61c79d4bd7414f9ca2d28006e9d15ef51.

---

<a id="pubmed-pmid-12151431-cetrorelix-v1"></a>

## Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'?

> PubMed lists PMID 12151431 in Human reproduction (Oxford, England) as Clinical Trial, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2002-08 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12151431-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-05-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12151431-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-12151431-cetrorelix-v1
- Content SHA-256: `3e7974ada04d2696d37a3cd6b0a1baf846f83dfe814fe112947b0a6137810a25`

### Claims and source pins

#### Headline

Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'? ([`pubmed-observation-pmid-12151431-2019-05-13-d013be82a3ec`](#source-pubmed-observation-pmid-12151431-2019-05-13-d013be82a3ec))

#### Summary

PubMed lists PMID 12151431 in Human reproduction (Oxford, England) as Clinical Trial, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2002-08 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12151431-2019-05-13-d013be82a3ec`](#source-pubmed-observation-pmid-12151431-2019-05-13-d013be82a3ec))

#### Paragraph 1

PubMed lists PMID 12151431 in Human reproduction (Oxford, England) as Clinical Trial, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2002-08 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12151431-2019-05-13-d013be82a3ec`](#source-pubmed-observation-pmid-12151431-2019-05-13-d013be82a3ec))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12151431-2019-05-13-d013be82a3ec`](#source-pubmed-observation-pmid-12151431-2019-05-13-d013be82a3ec))

### Sources

<a id="source-pubmed-observation-pmid-12151431-2019-05-13-d013be82a3ec"></a>
- **Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'? · retained source version 1:2019-05-13:current:d013be82a3ecf85bab66e3dff68cde0a89677e0f42b0864a8d0c087537ca7ae9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12151431/) (`pubmed-observation-pmid-12151431-2019-05-13-d013be82a3ec`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'?" Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-12151431-cetrorelix-v1 SHA-256: 3e7974ada04d2696d37a3cd6b0a1baf846f83dfe814fe112947b0a6137810a25.

---

<a id="pubmed-pmid-12448050-cetrorelix-v1"></a>

## \[Use of GnRH antagonists (cetrorelix) in assisted reproduction: first report in Mexican literature\].

> PubMed lists PMID 12448050 in Ginecologia y obstetricia de Mexico as Comparative Study, English Abstract, Journal Article, with publication-date metadata of 2002-09 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12448050-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-05-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12448050-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-12448050-cetrorelix-v1
- Content SHA-256: `03383ab4911e5f85daa6ee6e5de31a3f830be259a1d92eeead622bd69eebf4be`

### Claims and source pins

#### Headline

\[Use of GnRH antagonists (cetrorelix) in assisted reproduction: first report in Mexican literature\]. ([`pubmed-observation-pmid-12448050-2013-05-29-ab59338618ef`](#source-pubmed-observation-pmid-12448050-2013-05-29-ab59338618ef))

#### Summary

PubMed lists PMID 12448050 in Ginecologia y obstetricia de Mexico as Comparative Study, English Abstract, Journal Article, with publication-date metadata of 2002-09 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12448050-2013-05-29-ab59338618ef`](#source-pubmed-observation-pmid-12448050-2013-05-29-ab59338618ef))

#### Paragraph 1

PubMed lists PMID 12448050 in Ginecologia y obstetricia de Mexico as Comparative Study, English Abstract, Journal Article, with publication-date metadata of 2002-09 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12448050-2013-05-29-ab59338618ef`](#source-pubmed-observation-pmid-12448050-2013-05-29-ab59338618ef))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12448050-2013-05-29-ab59338618ef`](#source-pubmed-observation-pmid-12448050-2013-05-29-ab59338618ef))

### Sources

<a id="source-pubmed-observation-pmid-12448050-2013-05-29-ab59338618ef"></a>
- **\[Use of GnRH antagonists (cetrorelix) in assisted reproduction: first report in Mexican literature\]. · retained source version 1:2013-05-29:current:ab59338618ef701cb71d6c014491ad28722c5b512a23906f3a6413577f89a092** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12448050/) (`pubmed-observation-pmid-12448050-2013-05-29-ab59338618ef`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Use of GnRH antagonists (cetrorelix) in assisted reproduction: first report in Mexican literature\]." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-12448050-cetrorelix-v1 SHA-256: 03383ab4911e5f85daa6ee6e5de31a3f830be259a1d92eeead622bd69eebf4be.

---

<a id="pubmed-pmid-13678723-cetrorelix-v1"></a>

## Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer.

> PubMed lists PMID 13678723 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, and 1 more PubMed publication type, with publication-date metadata of 2003-09 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-13678723-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-13678723-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-13678723-cetrorelix-v1
- Content SHA-256: `27950c9c50f63d2bd4fdac1770dac743e1592cc9517a07e3f781f85bca1465dd`

### Claims and source pins

#### Headline

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. ([`pubmed-observation-pmid-13678723-2019-08-27-4e66d73cafb5`](#source-pubmed-observation-pmid-13678723-2019-08-27-4e66d73cafb5))

#### Summary

PubMed lists PMID 13678723 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, and 1 more PubMed publication type, with publication-date metadata of 2003-09 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-13678723-2019-08-27-4e66d73cafb5`](#source-pubmed-observation-pmid-13678723-2019-08-27-4e66d73cafb5))

#### Paragraph 1

PubMed lists PMID 13678723 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, and 1 more PubMed publication type, with publication-date metadata of 2003-09 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-13678723-2019-08-27-4e66d73cafb5`](#source-pubmed-observation-pmid-13678723-2019-08-27-4e66d73cafb5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-13678723-2019-08-27-4e66d73cafb5`](#source-pubmed-observation-pmid-13678723-2019-08-27-4e66d73cafb5))

### Sources

<a id="source-pubmed-observation-pmid-13678723-2019-08-27-4e66d73cafb5"></a>
- **Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. · retained source version 1:2019-08-27:current:4e66d73cafb5b7c676f92d5a82d1ef51604cbd5dbeaf43b872bc6cfde2f5581b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/13678723/) (`pubmed-observation-pmid-13678723-2019-08-27-4e66d73cafb5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-13678723-cetrorelix-v1 SHA-256: 27950c9c50f63d2bd4fdac1770dac743e1592cc9517a07e3f781f85bca1465dd.

---

<a id="pubmed-pmid-14757490-cetrorelix-v1"></a>

## Adsorption of the decapeptide Cetrorelix depends both on the composition of dissolution medium and the type of solid surface.

> PubMed lists PMID 14757490 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004-02 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-14757490-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-14757490-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-14757490-cetrorelix-v1
- Content SHA-256: `3250fe583fa51fee800fca8bda9a98c373ec192ef25081523e73e35a57019188`

### Claims and source pins

#### Headline

Adsorption of the decapeptide Cetrorelix depends both on the composition of dissolution medium and the type of solid surface. ([`pubmed-observation-pmid-14757490-2019-11-08-b8bb197989ec`](#source-pubmed-observation-pmid-14757490-2019-11-08-b8bb197989ec))

#### Summary

PubMed lists PMID 14757490 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004-02 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14757490-2019-11-08-b8bb197989ec`](#source-pubmed-observation-pmid-14757490-2019-11-08-b8bb197989ec))

#### Paragraph 1

PubMed lists PMID 14757490 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004-02 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14757490-2019-11-08-b8bb197989ec`](#source-pubmed-observation-pmid-14757490-2019-11-08-b8bb197989ec))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-14757490-2019-11-08-b8bb197989ec`](#source-pubmed-observation-pmid-14757490-2019-11-08-b8bb197989ec))

### Sources

<a id="source-pubmed-observation-pmid-14757490-2019-11-08-b8bb197989ec"></a>
- **Adsorption of the decapeptide Cetrorelix depends both on the composition of dissolution medium and the type of solid surface. · retained source version 1:2019-11-08:current:b8bb197989ec1a34c79d32b10809cf1d9920b937f6b5fc21ac907ba505182a40** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/14757490/) (`pubmed-observation-pmid-14757490-2019-11-08-b8bb197989ec`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Adsorption of the decapeptide Cetrorelix depends both on the composition of dissolution medium and the type of solid surface." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-14757490-cetrorelix-v1 SHA-256: 3250fe583fa51fee800fca8bda9a98c373ec192ef25081523e73e35a57019188.

---

<a id="pubmed-pmid-15019030-cetrorelix-v1"></a>

## Development and validation of a HPLC method for routine quantification of the decapeptide Cetrorelix in liposome dispersions.

> PubMed lists PMID 15019030 in Journal of pharmaceutical and biomedical analysis as Journal Article, Validation Study, with publication-date metadata of 2004-03-10 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15019030-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-12-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15019030-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-15019030-cetrorelix-v1
- Content SHA-256: `6264032511ed35cfb386c9171f8dcb704316689eabed30d7ceb320535a9b2888`

### Claims and source pins

#### Headline

Development and validation of a HPLC method for routine quantification of the decapeptide Cetrorelix in liposome dispersions. ([`pubmed-observation-pmid-15019030-2019-12-10-688479dff331`](#source-pubmed-observation-pmid-15019030-2019-12-10-688479dff331))

#### Summary

PubMed lists PMID 15019030 in Journal of pharmaceutical and biomedical analysis as Journal Article, Validation Study, with publication-date metadata of 2004-03-10 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15019030-2019-12-10-688479dff331`](#source-pubmed-observation-pmid-15019030-2019-12-10-688479dff331))

#### Paragraph 1

PubMed lists PMID 15019030 in Journal of pharmaceutical and biomedical analysis as Journal Article, Validation Study, with publication-date metadata of 2004-03-10 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15019030-2019-12-10-688479dff331`](#source-pubmed-observation-pmid-15019030-2019-12-10-688479dff331))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15019030-2019-12-10-688479dff331`](#source-pubmed-observation-pmid-15019030-2019-12-10-688479dff331))

### Sources

<a id="source-pubmed-observation-pmid-15019030-2019-12-10-688479dff331"></a>
- **Development and validation of a HPLC method for routine quantification of the decapeptide Cetrorelix in liposome dispersions. · retained source version 1:2019-12-10:current:688479dff33182d26757c29c2898973ace8c73a3960d0c4fbe21a447fa2a8418** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15019030/) (`pubmed-observation-pmid-15019030-2019-12-10-688479dff331`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Development and validation of a HPLC method for routine quantification of the decapeptide Cetrorelix in liposome dispersions." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-15019030-cetrorelix-v1 SHA-256: 6264032511ed35cfb386c9171f8dcb704316689eabed30d7ceb320535a9b2888.

---

<a id="pubmed-pmid-17020439-cetrorelix-v1"></a>

## Cetrorelix in the treatment of female infertility and endometriosis.

> PubMed lists PMID 17020439 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2006-10 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17020439-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-09-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17020439-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-17020439-cetrorelix-v1
- Content SHA-256: `73b45b1f55c5cabc69077feb09a93466847697186f2143136a43bd0d0e124ffc`

### Claims and source pins

#### Headline

Cetrorelix in the treatment of female infertility and endometriosis. ([`pubmed-observation-pmid-17020439-2019-09-17-9474faf123c1`](#source-pubmed-observation-pmid-17020439-2019-09-17-9474faf123c1))

#### Summary

PubMed lists PMID 17020439 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2006-10 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17020439-2019-09-17-9474faf123c1`](#source-pubmed-observation-pmid-17020439-2019-09-17-9474faf123c1))

#### Paragraph 1

PubMed lists PMID 17020439 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2006-10 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17020439-2019-09-17-9474faf123c1`](#source-pubmed-observation-pmid-17020439-2019-09-17-9474faf123c1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17020439-2019-09-17-9474faf123c1`](#source-pubmed-observation-pmid-17020439-2019-09-17-9474faf123c1))

### Sources

<a id="source-pubmed-observation-pmid-17020439-2019-09-17-9474faf123c1"></a>
- **Cetrorelix in the treatment of female infertility and endometriosis. · retained source version 1:2019-09-17:current:9474faf123c19667e6c7b262ad8008d0d7ab48b7774cb857c4e9415f30d5a40c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17020439/) (`pubmed-observation-pmid-17020439-2019-09-17-9474faf123c1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Cetrorelix in the treatment of female infertility and endometriosis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-17020439-cetrorelix-v1 SHA-256: 73b45b1f55c5cabc69077feb09a93466847697186f2143136a43bd0d0e124ffc.

---

<a id="pubmed-pmid-17934727-cetrorelix-v1"></a>

## In vivo biodistribution of an androgen receptor avid PET imaging agent 7-alpha-fluoro-17 alpha-methyl-5-alpha-dihydrotestosterone (\[(18)F\]FMDHT) in rats pretreated with cetrorelix, a GnRH antagonist.

> PubMed lists PMID 17934727 in European journal of nuclear medicine and molecular imaging as Journal Article, Research Support, N.I.H., Extramural, with publication-date metadata of 2007-10-13 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17934727-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17934727-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-17934727-cetrorelix-v1
- Content SHA-256: `b83dfdc61bfb7ba547b3067adcea5da88c6ff99eeb31b01b51f5c18772887324`

### Claims and source pins

#### Headline

In vivo biodistribution of an androgen receptor avid PET imaging agent 7-alpha-fluoro-17 alpha-methyl-5-alpha-dihydrotestosterone (\[(18)F\]FMDHT) in rats pretreated with cetrorelix, a GnRH antagonist. ([`pubmed-observation-pmid-17934727-2021-10-20-60ed16881a18`](#source-pubmed-observation-pmid-17934727-2021-10-20-60ed16881a18))

#### Summary

PubMed lists PMID 17934727 in European journal of nuclear medicine and molecular imaging as Journal Article, Research Support, N.I.H., Extramural, with publication-date metadata of 2007-10-13 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17934727-2021-10-20-60ed16881a18`](#source-pubmed-observation-pmid-17934727-2021-10-20-60ed16881a18))

#### Paragraph 1

PubMed lists PMID 17934727 in European journal of nuclear medicine and molecular imaging as Journal Article, Research Support, N.I.H., Extramural, with publication-date metadata of 2007-10-13 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17934727-2021-10-20-60ed16881a18`](#source-pubmed-observation-pmid-17934727-2021-10-20-60ed16881a18))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17934727-2021-10-20-60ed16881a18`](#source-pubmed-observation-pmid-17934727-2021-10-20-60ed16881a18))

### Sources

<a id="source-pubmed-observation-pmid-17934727-2021-10-20-60ed16881a18"></a>
- **In vivo biodistribution of an androgen receptor avid PET imaging agent 7-alpha-fluoro-17 alpha-methyl-5-alpha-dihydrotestosterone (\[(18)F\]FMDHT) in rats pretreated with cetrorelix, a GnRH antagonist. · retained source version 1:2021-10-20:current:60ed16881a18353ebc71ab7a72a08e6e99187a534ec100337a18c0cb638abaa7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17934727/) (`pubmed-observation-pmid-17934727-2021-10-20-60ed16881a18`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "In vivo biodistribution of an androgen receptor avid PET imaging agent 7-alpha-fluoro-17 alpha-methyl-5-alpha-dihydrotestosterone (\[(18)F\]FMDHT) in rats pretreated with cetrorelix, a GnRH antagonist." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-17934727-cetrorelix-v1 SHA-256: b83dfdc61bfb7ba547b3067adcea5da88c6ff99eeb31b01b51f5c18772887324.

---

<a id="pubmed-pmid-18855603-cetrorelix-v1"></a>

## Modification of the in vitro release profile of Cetrorelix by complexation with biophilic partners.

> PubMed lists PMID 18855603 in Current drug delivery as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-10 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18855603-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18855603-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-18855603-cetrorelix-v1
- Content SHA-256: `dc3eaeb975b25d3763138d9f9271cab73a7423916fa92a27dec38e4d244dc085`

### Claims and source pins

#### Headline

Modification of the in vitro release profile of Cetrorelix by complexation with biophilic partners. ([`pubmed-observation-pmid-18855603-2019-11-11-ef39ba1fb2cb`](#source-pubmed-observation-pmid-18855603-2019-11-11-ef39ba1fb2cb))

#### Summary

PubMed lists PMID 18855603 in Current drug delivery as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-10 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18855603-2019-11-11-ef39ba1fb2cb`](#source-pubmed-observation-pmid-18855603-2019-11-11-ef39ba1fb2cb))

#### Paragraph 1

PubMed lists PMID 18855603 in Current drug delivery as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-10 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18855603-2019-11-11-ef39ba1fb2cb`](#source-pubmed-observation-pmid-18855603-2019-11-11-ef39ba1fb2cb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18855603-2019-11-11-ef39ba1fb2cb`](#source-pubmed-observation-pmid-18855603-2019-11-11-ef39ba1fb2cb))

### Sources

<a id="source-pubmed-observation-pmid-18855603-2019-11-11-ef39ba1fb2cb"></a>
- **Modification of the in vitro release profile of Cetrorelix by complexation with biophilic partners. · retained source version 1:2019-11-11:current:ef39ba1fb2cb3f874fcc2917d485e0c27cde68b183f130ee0ea9c913b4560aa5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18855603/) (`pubmed-observation-pmid-18855603-2019-11-11-ef39ba1fb2cb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Modification of the in vitro release profile of Cetrorelix by complexation with biophilic partners." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-18855603-cetrorelix-v1 SHA-256: dc3eaeb975b25d3763138d9f9271cab73a7423916fa92a27dec38e4d244dc085.

---

<a id="pubmed-pmid-20514551-cetrorelix-v1"></a>

## Fluorescence spectroscopic determination of the critical aggregation concentration of the GnRH antagonists Cetrorelix, Teverelix and Ozarelix.

> PubMed lists PMID 20514551 in Journal of fluorescence as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-06-01 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20514551-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20514551-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-20514551-cetrorelix-v1
- Content SHA-256: `8f22f5bab2165537b456f5781e49a36f40be79f19b8e960814b96ae4d70096ee`

### Claims and source pins

#### Headline

Fluorescence spectroscopic determination of the critical aggregation concentration of the GnRH antagonists Cetrorelix, Teverelix and Ozarelix. ([`pubmed-observation-pmid-20514551-2021-10-20-2483352fef51`](#source-pubmed-observation-pmid-20514551-2021-10-20-2483352fef51))

#### Summary

PubMed lists PMID 20514551 in Journal of fluorescence as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-06-01 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20514551-2021-10-20-2483352fef51`](#source-pubmed-observation-pmid-20514551-2021-10-20-2483352fef51))

#### Paragraph 1

PubMed lists PMID 20514551 in Journal of fluorescence as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-06-01 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20514551-2021-10-20-2483352fef51`](#source-pubmed-observation-pmid-20514551-2021-10-20-2483352fef51))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20514551-2021-10-20-2483352fef51`](#source-pubmed-observation-pmid-20514551-2021-10-20-2483352fef51))

### Sources

<a id="source-pubmed-observation-pmid-20514551-2021-10-20-2483352fef51"></a>
- **Fluorescence spectroscopic determination of the critical aggregation concentration of the GnRH antagonists Cetrorelix, Teverelix and Ozarelix. · retained source version 1:2021-10-20:current:2483352fef51ba02c8a2ce2f9d4523a2fc7890644079c46264f25809fedf1e57** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20514551/) (`pubmed-observation-pmid-20514551-2021-10-20-2483352fef51`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Fluorescence spectroscopic determination of the critical aggregation concentration of the GnRH antagonists Cetrorelix, Teverelix and Ozarelix." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-20514551-cetrorelix-v1 SHA-256: 8f22f5bab2165537b456f5781e49a36f40be79f19b8e960814b96ae4d70096ee.

---

<a id="pubmed-pmid-21810087-cetrorelix-v1"></a>

## A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy.

> PubMed lists PMID 21810087 in The Australian & New Zealand journal of obstetrics & gynaecology as Journal Article, with publication-date metadata of 2011-08-02 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-21810087-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-21810087-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-21810087-cetrorelix-v1
- Content SHA-256: `e6b2b9bccd0c3a6ab0c5ffc60b684160d5b38af7eda94c863ae1e4acbc0ed895`

### Claims and source pins

#### Headline

A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy. ([`pubmed-observation-pmid-21810087-2013-11-21-59b0ddaca566`](#source-pubmed-observation-pmid-21810087-2013-11-21-59b0ddaca566))

#### Summary

PubMed lists PMID 21810087 in The Australian & New Zealand journal of obstetrics & gynaecology as Journal Article, with publication-date metadata of 2011-08-02 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21810087-2013-11-21-59b0ddaca566`](#source-pubmed-observation-pmid-21810087-2013-11-21-59b0ddaca566))

#### Paragraph 1

PubMed lists PMID 21810087 in The Australian & New Zealand journal of obstetrics & gynaecology as Journal Article, with publication-date metadata of 2011-08-02 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21810087-2013-11-21-59b0ddaca566`](#source-pubmed-observation-pmid-21810087-2013-11-21-59b0ddaca566))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-21810087-2013-11-21-59b0ddaca566`](#source-pubmed-observation-pmid-21810087-2013-11-21-59b0ddaca566))

### Sources

<a id="source-pubmed-observation-pmid-21810087-2013-11-21-59b0ddaca566"></a>
- **A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy. · retained source version 1:2013-11-21:current:59b0ddaca5661e06d62e07be94033f75960e22e56c7d23d19730eab6f7d1452a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/21810087/) (`pubmed-observation-pmid-21810087-2013-11-21-59b0ddaca566`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-21810087-cetrorelix-v1 SHA-256: e6b2b9bccd0c3a6ab0c5ffc60b684160d5b38af7eda94c863ae1e4acbc0ed895.

---

<a id="pubmed-pmid-22696667-cetrorelix-v1"></a>

## Use of cetrorelix in the investigation of testosterone excess in a postmenopausal woman.

> PubMed lists PMID 22696667 in BMJ case reports as Case Reports, Journal Article, with publication-date metadata of 2011-04-26 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22696667-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22696667-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-22696667-cetrorelix-v1
- Content SHA-256: `cb0588d828847f7b16500a5e199c39cbdb1b2d641e5c98032c5dab907c23b051`

### Claims and source pins

#### Headline

Use of cetrorelix in the investigation of testosterone excess in a postmenopausal woman. ([`pubmed-observation-pmid-22696667-2021-10-21-bbbdf023df70`](#source-pubmed-observation-pmid-22696667-2021-10-21-bbbdf023df70))

#### Summary

PubMed lists PMID 22696667 in BMJ case reports as Case Reports, Journal Article, with publication-date metadata of 2011-04-26 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22696667-2021-10-21-bbbdf023df70`](#source-pubmed-observation-pmid-22696667-2021-10-21-bbbdf023df70))

#### Paragraph 1

PubMed lists PMID 22696667 in BMJ case reports as Case Reports, Journal Article, with publication-date metadata of 2011-04-26 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22696667-2021-10-21-bbbdf023df70`](#source-pubmed-observation-pmid-22696667-2021-10-21-bbbdf023df70))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22696667-2021-10-21-bbbdf023df70`](#source-pubmed-observation-pmid-22696667-2021-10-21-bbbdf023df70))

### Sources

<a id="source-pubmed-observation-pmid-22696667-2021-10-21-bbbdf023df70"></a>
- **Use of cetrorelix in the investigation of testosterone excess in a postmenopausal woman. · retained source version 1:2021-10-21:current:bbbdf023df70645d9cff51987bac1e534833a45d5d99dd25da12f366aff252de** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22696667/) (`pubmed-observation-pmid-22696667-2021-10-21-bbbdf023df70`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Use of cetrorelix in the investigation of testosterone excess in a postmenopausal woman." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-22696667-cetrorelix-v1 SHA-256: cb0588d828847f7b16500a5e199c39cbdb1b2d641e5c98032c5dab907c23b051.

---

<a id="pubmed-pmid-33548873-cetrorelix-v1"></a>

## Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds.

> PubMed lists PMID 33548873 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2021-01-27 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33548873-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-06-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33548873-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-33548873-cetrorelix-v1
- Content SHA-256: `b32024ad653eb0efc54a7def42a3ff66480c12201a22ba7b3f434b0acbe39f28`

### Claims and source pins

#### Headline

Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds. ([`pubmed-observation-pmid-33548873-2021-06-17-48afb56189b4`](#source-pubmed-observation-pmid-33548873-2021-06-17-48afb56189b4))

#### Summary

PubMed lists PMID 33548873 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2021-01-27 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33548873-2021-06-17-48afb56189b4`](#source-pubmed-observation-pmid-33548873-2021-06-17-48afb56189b4))

#### Paragraph 1

PubMed lists PMID 33548873 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2021-01-27 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33548873-2021-06-17-48afb56189b4`](#source-pubmed-observation-pmid-33548873-2021-06-17-48afb56189b4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33548873-2021-06-17-48afb56189b4`](#source-pubmed-observation-pmid-33548873-2021-06-17-48afb56189b4))

### Sources

<a id="source-pubmed-observation-pmid-33548873-2021-06-17-48afb56189b4"></a>
- **Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds. · retained source version 1:2021-06-17:current:48afb56189b4b2b496000cb71d1282c18f06df9bdda6e5c6caef34aed7ba0a65** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33548873/) (`pubmed-observation-pmid-33548873-2021-06-17-48afb56189b4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-33548873-cetrorelix-v1 SHA-256: b32024ad653eb0efc54a7def42a3ff66480c12201a22ba7b3f434b0acbe39f28.

---

<a id="pubmed-pmid-33611089-cetrorelix-v1"></a>

## Identification and structural elucidation of a new cetrorelix methylene dimer impurity in cetrorelix acetate by using LC-MS/MS.

> PubMed lists PMID 33611089 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2021-02-03 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33611089-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-06-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33611089-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-33611089-cetrorelix-v1
- Content SHA-256: `585eb8e15e22d40affcf81f9f1bf74ad3997c9ce7f07a80005744c2912c0e429`

### Claims and source pins

#### Headline

Identification and structural elucidation of a new cetrorelix methylene dimer impurity in cetrorelix acetate by using LC-MS/MS. ([`pubmed-observation-pmid-33611089-2021-06-17-ce8bc2a6a59b`](#source-pubmed-observation-pmid-33611089-2021-06-17-ce8bc2a6a59b))

#### Summary

PubMed lists PMID 33611089 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2021-02-03 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33611089-2021-06-17-ce8bc2a6a59b`](#source-pubmed-observation-pmid-33611089-2021-06-17-ce8bc2a6a59b))

#### Paragraph 1

PubMed lists PMID 33611089 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2021-02-03 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33611089-2021-06-17-ce8bc2a6a59b`](#source-pubmed-observation-pmid-33611089-2021-06-17-ce8bc2a6a59b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33611089-2021-06-17-ce8bc2a6a59b`](#source-pubmed-observation-pmid-33611089-2021-06-17-ce8bc2a6a59b))

### Sources

<a id="source-pubmed-observation-pmid-33611089-2021-06-17-ce8bc2a6a59b"></a>
- **Identification and structural elucidation of a new cetrorelix methylene dimer impurity in cetrorelix acetate by using LC-MS/MS. · retained source version 1:2021-06-17:current:ce8bc2a6a59ba4112512b94477c781c136571a4e1c07d6812e616d1425a512e7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33611089/) (`pubmed-observation-pmid-33611089-2021-06-17-ce8bc2a6a59b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Identification and structural elucidation of a new cetrorelix methylene dimer impurity in cetrorelix acetate by using LC-MS/MS." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-33611089-cetrorelix-v1 SHA-256: 585eb8e15e22d40affcf81f9f1bf74ad3997c9ce7f07a80005744c2912c0e429.

---

<a id="pubmed-pmid-36630767-cetrorelix-v1"></a>

## Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model…

> PubMed lists PMID 36630767 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2022-12-31 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36630767-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36630767-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-36630767-cetrorelix-v1
- Content SHA-256: `4a3dbae269754a555586e2843308b6f828a91576980f92429420071c5bfa2fff`

### Claims and source pins

#### Headline

Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model… ([`pubmed-observation-pmid-36630767-2026-01-27-6486dbc996a0`](#source-pubmed-observation-pmid-36630767-2026-01-27-6486dbc996a0))

#### Summary

PubMed lists PMID 36630767 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2022-12-31 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36630767-2026-01-27-6486dbc996a0`](#source-pubmed-observation-pmid-36630767-2026-01-27-6486dbc996a0))

#### Paragraph 1

PubMed lists PMID 36630767 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2022-12-31 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36630767-2026-01-27-6486dbc996a0`](#source-pubmed-observation-pmid-36630767-2026-01-27-6486dbc996a0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36630767-2026-01-27-6486dbc996a0`](#source-pubmed-observation-pmid-36630767-2026-01-27-6486dbc996a0))

### Sources

<a id="source-pubmed-observation-pmid-36630767-2026-01-27-6486dbc996a0"></a>
- **Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model compounds. · retained source version 1:2026-01-27:current:6486dbc996a05ed84ffa158e6c0ad63f345feec48cf58bc2d17624e6e511b1f9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36630767/) (`pubmed-observation-pmid-36630767-2026-01-27-6486dbc996a0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model…." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-36630767-cetrorelix-v1 SHA-256: 4a3dbae269754a555586e2843308b6f828a91576980f92429420071c5bfa2fff.

---

<a id="pubmed-pmid-37223762-cetrorelix-v1"></a>

## Cetrorelix in reproductive medicine.

> PubMed lists PMID 37223762 in F&S reports as Journal Article, with publication-date metadata of 2022-11-21 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37223762-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-09-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37223762-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-37223762-cetrorelix-v1
- Content SHA-256: `02d13bb4998c57ff3e397e422e819e44fd6e1f795f877bf06837ac5657622fe2`

### Claims and source pins

#### Headline

Cetrorelix in reproductive medicine. ([`pubmed-observation-pmid-37223762-2024-09-18-e39775b63994`](#source-pubmed-observation-pmid-37223762-2024-09-18-e39775b63994))

#### Summary

PubMed lists PMID 37223762 in F&S reports as Journal Article, with publication-date metadata of 2022-11-21 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37223762-2024-09-18-e39775b63994`](#source-pubmed-observation-pmid-37223762-2024-09-18-e39775b63994))

#### Paragraph 1

PubMed lists PMID 37223762 in F&S reports as Journal Article, with publication-date metadata of 2022-11-21 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37223762-2024-09-18-e39775b63994`](#source-pubmed-observation-pmid-37223762-2024-09-18-e39775b63994))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37223762-2024-09-18-e39775b63994`](#source-pubmed-observation-pmid-37223762-2024-09-18-e39775b63994))

### Sources

<a id="source-pubmed-observation-pmid-37223762-2024-09-18-e39775b63994"></a>
- **Cetrorelix in reproductive medicine. · retained source version 1:2024-09-18:current:e39775b63994b2ad47239c7661e536f672834f92c5db3d0153c1c5aa53d1b7cf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37223762/) (`pubmed-observation-pmid-37223762-2024-09-18-e39775b63994`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Cetrorelix in reproductive medicine." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-37223762-cetrorelix-v1 SHA-256: 02d13bb4998c57ff3e397e422e819e44fd6e1f795f877bf06837ac5657622fe2.

---

<a id="pubmed-pmid-40386934-cetrorelix-v1"></a>

## Synthesis of Diastereomerically Pure Cetrorelix Acetate by Using Fmoc Solid-Phase Peptide Synthesis (SPPS) Strategy: A Commercially Viable Approach.

> PubMed lists PMID 40386934 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, with publication-date metadata of 2025-06 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40386934-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40386934-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-40386934-cetrorelix-v1
- Content SHA-256: `30b6101ea5a8b45df86bb34bd7eae53706135d1fe6988742d7ef54deae24f754`

### Claims and source pins

#### Headline

Synthesis of Diastereomerically Pure Cetrorelix Acetate by Using Fmoc Solid-Phase Peptide Synthesis (SPPS) Strategy: A Commercially Viable Approach. ([`pubmed-observation-pmid-40386934-2026-01-27-695b58a1f5b2`](#source-pubmed-observation-pmid-40386934-2026-01-27-695b58a1f5b2))

#### Summary

PubMed lists PMID 40386934 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, with publication-date metadata of 2025-06 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40386934-2026-01-27-695b58a1f5b2`](#source-pubmed-observation-pmid-40386934-2026-01-27-695b58a1f5b2))

#### Paragraph 1

PubMed lists PMID 40386934 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, with publication-date metadata of 2025-06 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40386934-2026-01-27-695b58a1f5b2`](#source-pubmed-observation-pmid-40386934-2026-01-27-695b58a1f5b2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40386934-2026-01-27-695b58a1f5b2`](#source-pubmed-observation-pmid-40386934-2026-01-27-695b58a1f5b2))

### Sources

<a id="source-pubmed-observation-pmid-40386934-2026-01-27-695b58a1f5b2"></a>
- **Synthesis of Diastereomerically Pure Cetrorelix Acetate by Using Fmoc Solid-Phase Peptide Synthesis (SPPS) Strategy: A Commercially Viable Approach. · retained source version 1:2026-01-27:current:695b58a1f5b2d08d6b322a052811ef5924435be61f7a2c5a5f81937d76c40405** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40386934/) (`pubmed-observation-pmid-40386934-2026-01-27-695b58a1f5b2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Synthesis of Diastereomerically Pure Cetrorelix Acetate by Using Fmoc Solid-Phase Peptide Synthesis (SPPS) Strategy: A Commercially Viable Approach." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-40386934-cetrorelix-v1 SHA-256: 30b6101ea5a8b45df86bb34bd7eae53706135d1fe6988742d7ef54deae24f754.

---

<a id="pubmed-pmid-42243608-cetrorelix-v1"></a>

## Comparison of Chitosan-Poloxamer Nanoparticles and Poloxamer-based In-Situ Forming Gel for Nose-to-Brain Delivery of Cetrorelix: In Vitro and Pharmacokinetic Studies in Rats.

> PubMed lists PMID 42243608 in AAPS PharmSciTech as Journal Article, Comparative Study, with publication-date metadata of 2026-06-04 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42243608-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42243608-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-42243608-cetrorelix-v1
- Content SHA-256: `3195d0b497febae81b502eb5249d738a6fc77dbe8e873bac07cebaac05602795`

### Claims and source pins

#### Headline

Comparison of Chitosan-Poloxamer Nanoparticles and Poloxamer-based In-Situ Forming Gel for Nose-to-Brain Delivery of Cetrorelix: In Vitro and Pharmacokinetic Studies in Rats. ([`pubmed-observation-pmid-42243608-2026-09-24-d20cdab6aac4`](#source-pubmed-observation-pmid-42243608-2026-09-24-d20cdab6aac4))

#### Summary

PubMed lists PMID 42243608 in AAPS PharmSciTech as Journal Article, Comparative Study, with publication-date metadata of 2026-06-04 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42243608-2026-09-24-d20cdab6aac4`](#source-pubmed-observation-pmid-42243608-2026-09-24-d20cdab6aac4))

#### Paragraph 1

PubMed lists PMID 42243608 in AAPS PharmSciTech as Journal Article, Comparative Study, with publication-date metadata of 2026-06-04 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42243608-2026-09-24-d20cdab6aac4`](#source-pubmed-observation-pmid-42243608-2026-09-24-d20cdab6aac4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42243608-2026-09-24-d20cdab6aac4`](#source-pubmed-observation-pmid-42243608-2026-09-24-d20cdab6aac4))

### Sources

<a id="source-pubmed-observation-pmid-42243608-2026-09-24-d20cdab6aac4"></a>
- **Comparison of Chitosan-Poloxamer Nanoparticles and Poloxamer-based In-Situ Forming Gel for Nose-to-Brain Delivery of Cetrorelix: In Vitro and Pharmacokinetic Studies in Rats. · retained source version 1:2026-09-24:current:d20cdab6aac4c8df170ef6bc966c2fb82be725e8626db342dfcf7628c9a89c26** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42243608/) (`pubmed-observation-pmid-42243608-2026-09-24-d20cdab6aac4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Comparison of Chitosan-Poloxamer Nanoparticles and Poloxamer-based In-Situ Forming Gel for Nose-to-Brain Delivery of Cetrorelix: In Vitro and Pharmacokinetic Studies in Rats." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-42243608-cetrorelix-v1 SHA-256: 3195d0b497febae81b502eb5249d738a6fc77dbe8e873bac07cebaac05602795.

---

<a id="pubmed-pmid-7531902-cetrorelix-v1"></a>

## Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord.

> PubMed lists PMID 7531902 in Urology as Clinical Trial, Journal Article, with publication-date metadata of 1995-02 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-7531902-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-07-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-7531902-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-7531902-cetrorelix-v1
- Content SHA-256: `9bb87ea55bc0ada8be311525941e581bf4a70c6aceba95031888f09870a7ae5f`

### Claims and source pins

#### Headline

Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. ([`pubmed-observation-pmid-7531902-2019-07-14-f19c6aa3c5f5`](#source-pubmed-observation-pmid-7531902-2019-07-14-f19c6aa3c5f5))

#### Summary

PubMed lists PMID 7531902 in Urology as Clinical Trial, Journal Article, with publication-date metadata of 1995-02 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7531902-2019-07-14-f19c6aa3c5f5`](#source-pubmed-observation-pmid-7531902-2019-07-14-f19c6aa3c5f5))

#### Paragraph 1

PubMed lists PMID 7531902 in Urology as Clinical Trial, Journal Article, with publication-date metadata of 1995-02 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7531902-2019-07-14-f19c6aa3c5f5`](#source-pubmed-observation-pmid-7531902-2019-07-14-f19c6aa3c5f5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-7531902-2019-07-14-f19c6aa3c5f5`](#source-pubmed-observation-pmid-7531902-2019-07-14-f19c6aa3c5f5))

### Sources

<a id="source-pubmed-observation-pmid-7531902-2019-07-14-f19c6aa3c5f5"></a>
- **Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. · retained source version 1:2019-07-14:current:f19c6aa3c5f5fc588921856a26f30dc90a02ff70ffa7ad294ae28aea6b01e53d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/7531902/) (`pubmed-observation-pmid-7531902-2019-07-14-f19c6aa3c5f5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-7531902-cetrorelix-v1 SHA-256: 9bb87ea55bc0ada8be311525941e581bf4a70c6aceba95031888f09870a7ae5f.

---

<a id="pubmed-pmid-9363724-cetrorelix-v1"></a>

## Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix.

> PubMed lists PMID 9363724 in Human reproduction (Oxford, England) as Clinical Trial, Journal Article, with publication-date metadata of 1997-09 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9363724-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-05-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9363724-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-9363724-cetrorelix-v1
- Content SHA-256: `5856d99a7f225b1e46b86e37776090b4aa4915f67c68dfcf9f299265bdb4bad1`

### Claims and source pins

#### Headline

Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. ([`pubmed-observation-pmid-9363724-2019-05-12-3f2f0f0ad015`](#source-pubmed-observation-pmid-9363724-2019-05-12-3f2f0f0ad015))

#### Summary

PubMed lists PMID 9363724 in Human reproduction (Oxford, England) as Clinical Trial, Journal Article, with publication-date metadata of 1997-09 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9363724-2019-05-12-3f2f0f0ad015`](#source-pubmed-observation-pmid-9363724-2019-05-12-3f2f0f0ad015))

#### Paragraph 1

PubMed lists PMID 9363724 in Human reproduction (Oxford, England) as Clinical Trial, Journal Article, with publication-date metadata of 1997-09 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9363724-2019-05-12-3f2f0f0ad015`](#source-pubmed-observation-pmid-9363724-2019-05-12-3f2f0f0ad015))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9363724-2019-05-12-3f2f0f0ad015`](#source-pubmed-observation-pmid-9363724-2019-05-12-3f2f0f0ad015))

### Sources

<a id="source-pubmed-observation-pmid-9363724-2019-05-12-3f2f0f0ad015"></a>
- **Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. · retained source version 1:2019-05-12:current:3f2f0f0ad015d8999d62a0328014bb790104899eee37df5d82c2abdad64872ca** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9363724/) (`pubmed-observation-pmid-9363724-2019-05-12-3f2f0f0ad015`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-9363724-cetrorelix-v1 SHA-256: 5856d99a7f225b1e46b86e37776090b4aa4915f67c68dfcf9f299265bdb4bad1.

---

<a id="pubmed-pmid-9688409-cetrorelix-v1"></a>

## Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix.

> PubMed lists PMID 9688409 in Human reproduction (Oxford, England) as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1998-06 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9688409-cetrorelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-05-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9688409-cetrorelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-9688409-cetrorelix-v1
- Content SHA-256: `8d81ff76a458135c220b288a1aaafc1aa614fa26f398b04dc0a4e392bf3df3ab`

### Claims and source pins

#### Headline

Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. ([`pubmed-observation-pmid-9688409-2019-05-12-41144fae289a`](#source-pubmed-observation-pmid-9688409-2019-05-12-41144fae289a))

#### Summary

PubMed lists PMID 9688409 in Human reproduction (Oxford, England) as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1998-06 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9688409-2019-05-12-41144fae289a`](#source-pubmed-observation-pmid-9688409-2019-05-12-41144fae289a))

#### Paragraph 1

PubMed lists PMID 9688409 in Human reproduction (Oxford, England) as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1998-06 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9688409-2019-05-12-41144fae289a`](#source-pubmed-observation-pmid-9688409-2019-05-12-41144fae289a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9688409-2019-05-12-41144fae289a`](#source-pubmed-observation-pmid-9688409-2019-05-12-41144fae289a))

### Sources

<a id="source-pubmed-observation-pmid-9688409-2019-05-12-41144fae289a"></a>
- **Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. · retained source version 1:2019-05-12:current:41144fae289a0d4b7b3737394614f8549281f32720d90923a11ddee89d652464** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9688409/) (`pubmed-observation-pmid-9688409-2019-05-12-41144fae289a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/cetrorelix.json#pubmed-pmid-9688409-cetrorelix-v1 SHA-256: 8d81ff76a458135c220b288a1aaafc1aa614fa26f398b04dc0a4e392bf3df3ab.

